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Abstract 
Computational Studies of Melatonin Analogues 
Melatonin (MLT, N-Acetyl-5-methoxytryptamine), a naturally occurring hormone 
produced by the pineal gland, plays a crucial role in the regulation of circadian rhythms. 
Melatonin supplements are utilized in treating various sleep disorders, but detrimental side 
effects currently discourages its use in space. Computer generated molecular models of 
MLT analogues were studied with the purpose of resolving the deficiencies within existing 
therapeutic agents by constructing an enhanced MLT analogue. The MT receptor binding 
data for each analogue was obtained from the literature and Sybyl 6.9 was used to perform 
3-D quantitative structure-activity relationship (QSAR) studies on eight data sets, using the 
comparative molecular field analysis (CoMF A) and comparative molecular similarity 
indices analysis (CoMSIA) methods. The predictive capabilities of each mathematical 
model were tested and structural changes, which most effectively increased the predicted 
activities for each set, were noted. The models consistently indicated that a steric increase 
ofthe methoxy group would improve the activity ofMLT. 
1 
I. Introduction 
3 ... 2 ... 1 ... Blast-offi With a deafening roar, a space shuttle is launched for its 
mission in space. Such an event captures the attention ofthousands of people and their 
eyes become glued to the scene as they wait with breathless anticipation to see another 
successful space take-off. Outer space has been an intriguing unknown throughout the 
ages. Each space probe sent out and mission undertaken gives scientists new pieces of data 
that serve to increase their knowledge ofthe vast expanse that we label outer space. 
However, space exploration is constrained by the limited amount of time that 
astronauts are able to spend in space during one space mission. One reason that longer 
space missions are currently not practical is that astronauts have difficulty sleeping in 
space. When they do sleep, it is not a deep, restful sleep. Lack of sleep, in addition to a 
reduction in the total amount oftime slept, is a source of concern in space and rightfully 
so. It is a well-known fact that adequate sleep is essential for optimal mental and physical 
performance, both of which are high priorities on a space mission. Fatigue is a serious 
problem because it affects performance by causing increased irritability, diminished 
concentration, slower reaction time and an increased risk of accidents. 
Melatonin and its derivatives have been proposed as a potential solution to help 
alleviate this major health problem. A naturally occurring neurohormone, melatonin (N-
acetyl-5-methosyindolamine) is produced by the pineal gland. 1•17 The synthesis and release 
of melatonin is triggered by darkness and suppressed by light.4 Melatonin has several 
functions, including control of the function of the adrenocortical and thyroid glands, testes, 
and ovaries, oxidant/antioxidant regulation, free radical scavenging, thermoregulation, and 
support ofthe immune response against viral infections. 18•19 Nevertheless, the most 
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important property of melatonin, in regards to this research project, is the sleep-inducing 
effect it has on the body.10 Melatonin plays a crucial role in the daily regulation of 
circadian rhythms. 14 Our body's master clock naturally produces cycles that are slightly 
longer than earth's day.20 A daily adjustment is necessary to prevent our body's biological 
night and day from getting out of sync with the environment. On earth, it simply resets 
itself after exposure to the brightness of daytime sunlight. 20 However, in space, astronauts 
are subjected to irregular light and dark hours which interfere with their bodies' biological 
clocks. 20 Consequently, astronauts sleep poorly in space, and when they do sleep, it is not a 
refreshing sleep. 
Melatonin supplements are presently used to minimize jet-lag, regulate delayed 
sleep-phase syndrome, control seasonal depression, and also to treat disorders resulting 
from shift work disturbances.2 But its use in space is currently prevented on account of its 
short biological half-life, lack of selectivity, poor oral bioavailability, and detrimental side-
effects such as drowsiness, headaches, stomach cramps, dizziness, irritability, depression, 
and slower reaction times. 18' 21 
Through previous research, it has been discovered that the actions of melatonin are 
the consequence ofhigh affinity bonding receptors located in the brain, kidneys, 
adipocytes, retina, blood vessels, and gastrointestinal tract. 7 Three distinct melatonin 
receptor subtypes, classified as MT1, MT2, and MT3, have been identified.6 The MT1 
receptor is localized in the suprachiasmatic nucleus (SCN) of the hypothalamus and the 
MT 2 receptor is found in the SCN and retina 3 MT 1 and MT 2 have both been found in 
mammal tissues and are both G-protein-coupled receptors; MT 3 has been identified as 
being a homologue of the human quinine reductase 2. 12 Each of the receptors performs a 
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different function. MTt is believed to control melatonin's circadian and reproductive 
actions, while MT 2 modulates circadian rhythms and visual functions. 5 The function of 
MT3 has not been as thoroughly investigated, but it is thought to be involved with 
detoxifying processes.12 Although previous studies have provided insights into the 
molecular requirements of melatonin's specific interaction with MT1 and MT2 receptors, 
the results have not led to a solution for sleep-related problems in space. The goal is a new, 
effective melatonin analogue able to activate all the necessary physiological processes 
required for a healthy, wakeful state in astronauts, with minimal side effects. 
In this study, molecular models were computer-generated for melatonin with the 
purpose of resolving the deficiencies of existing therapeutic agents for sleep disorders and 
designing measures against the harmful effects resulting from insufficient sleep of 
astronauts during space missions. Operating under the assumption that changes in 
biological activities are related to the physicochemical properties ofthe compound, the 
mathematical nature of the relationship was examined. The specific goals of this project 
were to: 1) Create databases of melatonin analogues containing indicators ofbiological and 
physicochemical properties by retrieving data from the literature. 2) Derive mathematical 
models relating to biological activity and changes in molecular properties using 
Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity 
Indices Analysis (CoMSIA). 3) Test the predictive capabilities ofthe mathematical 
models, with the intent that, after careful analysis of these models, modifications that 
would enhance the activity of melatonin could be suggested. 
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II. Materials and Methods 
This research was performed using Silicon Graphics Inc. (SGI) work stations, as 
well as Dell650n work stations, to run Sybyl 6.9 (TRIPOS Associates Inc., St. Louis, 
MO), a Linux-based molecular modeling program. In order to discover new insights into 
the structural requirements for melatonin's biological activity, 3-D quantitative structure-
activity relationships (QSAR) were determined using the comparative molecular field 
analysis (CoMF A) and comparative molecular similarity indices analysis (CoMSIA) 
methods. These methods are useful because they generate Y-D models that graphically 
represent the structure-activity relationship among a given series of compounds. Both of 
these QSAR methods are based on the assumption that changes in binding affinities of 
compounds are related to changes in molecular properties which are represented by 
fields.22 The two methods differ only in the implementation ofthe fields. The goal ofthis 
molecular modeling research was to first gain an understanding of the fundamental 
relationship between the chemical and physical properties of a molecule, its chemical 
structure, and the 3-D structure it adopts. By relating these properties to the biological 
function of a molecule, this new understanding was used to logically design molecules of 
altered, or enhanced, function. 
For this research project, information from the literature was gathered on eight 
unique data sets of melatonin analogues. The names and structures used to generate the 
QSARs are shown in Figures 1-8. Each compound was represented by a single molecular 
model. Based on the information in the literature, models were manually sketched and 
minimized using the standard Tripos force field. 23 The purpose of minimization is to 
reduce the internal strain energy of a compound by adjusting its bond angles and torsions. 
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Once minimized, the Gasteiger-Huckel atomic partial charges of each compound were 
computed. After these initial steps were completed, MOPAC, which stands for molecular 
orbital package, was run on each compound. 23 MOP AC is a general-purpose semi empirical 
molecular orbital package for the study of molecular structures. It obtains molecular 
orbitals, as well as the heat of formation and its derivatives, for a compound; it then uses 
these results for the calculations. The two functions of MOP AC are to apply an external 
electric field and to optimize the geometry of a compound. MOPAC starts with the 
approximation of the desired geometry previously found by minimization and, by 
calculating the forces acting on the system, changes the geometry of a compound until the 
energy is at a minimum. MOP AC-determined atomic charges and the new geometries were 
applied to the compounds. The MOPAC setup was as follows: Method - AMI, State -
singlet, Net Charge - 0 u.e., Time Limit - 7200 s, Convergence - Normal and Precise, 
Optimization - Full, and Keyword - mmok. AMI (Austin Model 1) is parameterized to be 
especially useful for hydrocarbons and other polar structures that have appreciable 
hydrogen bonding interactions. The singlet setting constrains the choice of energy states to 
singlets only. All ofthe compounds studied had a net charge ofO; however, when the 
system being studied is an ion, a charge must be supplied. The full optimization setting 
optimizes all bonds, angles, and torsion angles. The MOP AC keyword mmok uses 
molecular mechanics correction to carbon, oxygen, nitrogen, and hydrogen bonds. 
Next, the compounds in each database were aligned with a chosen reference 
compound. The idea underlying CoMF A and CoMSIA is that differences in a target 
property are related to the differences in the shapes of the non-covalent fields surrounding 
the tested molecules. The magnitudes of each compound's steric and electrostatic fields are 
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sampled at regular intervals throughout a defined region. The positioning of a molecular 
model with a fixed lattice is the most important input variable because the relative 
interaction energies depend strongly on relative molecular positions?5 Without close 
alignment, accurate comparisons of their molecular properties cannot be made. If, after the 
initial run, the results were not satisfactory, then closer alignment was achieved by twisting 
or turning the side chains of each individual compound. After modification, each 
compound was manually realigned to the reference compound. MOP AC was rerun on 
these modified compounds, but only the atomic charges were applied the second time. 
I 
Finally, the aligned compounds containing MOP AC charges were put into a database. 
For each database, a CoMF A spreadsheet and a CoMSIA spreadsheet were created 
for each data set of property variables. The experimentally determined biological activities, 
which were obtained from the literature, were entered in the first column ofthe 
spreadsheets. CoMF A and CoMSIA columns were then generated; the settings were left on 
default. The CoMF A setup was as follows: CoMF A Field Class- Tripos Standard, Field 
Values - Type(s): Both, Dielectric: Distance, Smoothing: None, Drop Electrostatics: 
Within Steric Cutoff for Each Row, Cutoffs- Steric: 30.0 kcal/mol, Electrostatic: 30.0 
kcal/mol, Transition: Smooth, and Region: Create Automatically. The CoMSIA setup was 
as follows: Field Parameters- Attenuation Factor: 0.3 and Region: Create Automatically. 
Each CoMFNCoMSIA row in the column corresponds directly to the field ofthe 
corresponding molecule. CoMFA generates a column containing information about sterics, 
or bulk, a column containing information about electrostatics, or charge, and a column 
containing information on both sterics and electrostatics. CoMSIA is slightly different and 
generates a column containing steric and electrostatic field information, a hydrogen donor 
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and acceptor column, and a hydrophobic column, which indicates where interactions with 
water would be negative or favorable.24 Both of these methods use probe atoms to analyze 
the shapes of the fields surrounding the tested compounds to fmd similarities and 
differences among the compounds of interest which can be related to biological activity. 
QSAR Partial Least Squares (PLS) was run on each spreadsheet using the CoMF A 
or CoMSIA information. Although the rationale behind computing CoMF A and CoMSIA 
fields is different, they are technically of equivalent form, so the subsequent PLS analyses 
are identically performed.25 Column One, containing the biological activities, was 
designated as being the dependent column. The PLS method in Sybyl6.9 was used to 
I 
extract a QSAR relationship from the data tables; this method attempts to determine the 
relationship between the CoMF NCoMSIA values and the known experimental activity of 
each molecule. Least Squares, or linear regression, is commonly used to draw the best 
straight line between many data points. Partial Least Squares is the same idea, but it 
involves fitting many x's, all the molecular properties, to one y, which is the biological 
activity.24 The ultimate goal ofQSAR analyses is the prediction ofbiological activities of 
molecules not yet synthesized. 
The first step in QSAR PLS was conducting a Leave-One-Out cross-validation run. 
The number of components was set to 6; these were selected by the standard PLS 
algorithm and then cross-validated in order of their correlation with the dependent 
variable?5 During this run, the computer leaves out one compound and uses a model 
created by the remaining compounds to predict the activity of the left-out compound. It 
then compares the predicted activity to the known activity to see how accurate the 
prediction was. Cross-validation evaluates a model not by how well it fits data, but by how 
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well it predicts data 24 When finished, the optimum number of components for the best 
model, the model which had the smallest difference between the predicted and actual 
dependent property values, and the corresponding correlation coefficient, or Q2 value, were 
displayed and recorded. Q2 indicates how well the model was able to predict the activities 
of the left out compounds. Q2 values range from 0 to plus or minus 1. A Q2 of plus 1 would 
indicate a model with perfect positive correlation, meaning that high and low field values 
are observed at corresponding spatial locations, while a Q2 of 0 would indicate a model 
with dissimilar fields and therefore lacking any type of predictive power.26 Negative values 
signify that the biological property values are better estimated by the mean of all values 
than by the model under consideration. 
Next, a No Validation PLS run was conducted using the optimum number of 
components as previously determined by the cross-validation analysis. The No Validation 
PLS runs reported explanatory R2 values, standard error of estimate, F values, and the 
probability ofR2 equaling 0. R2 gives the fraction of the variance that is explained by the 
regression line; it is the correlation coefficient that indicates how accurately the model 
containing all the compounds was able to predict the activity ofthe compounds. The more 
scattered the data points, the lower R2 will be. Just like Q2, the R2 values also range from 0 
to plus or minus 1. The residuals are one way to quantify the error in the estimate for 
individual values calculated by the regression equation in a data set. The standard error of 
estimate for the residuals is calculated by taking the root-mean-square of the residuals. The 
F value indicates the probability of a true relationship, or the significance level of a 
multiple linear regression model; it is the ratio between explained and unexplained 
variance for a given number of degrees of freedom. The larger the F value, the greater the 
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probability that the QSAR equation is significant. All of these numbers were recorded for 
each ofthe different analyses. 
Once a PLS analysis has been completed, the QSAR results are visually 
represented by a three-dimensional model using a specific coloring scheme to indicate the 
different fields and a scatter plot showing the residuals between the experimental activities 
and the predicted activities. The visualization of the results of the comparative analyses in 
terms of field contributions was performed by means of computer graphics enclosing the 
volumes above and below particular field values with colored polyhedra.23 Evaluation of 
the field values indicates in which spatial areas significant variations among the 
compounds occur that correlate with the dependent property variable. In general, the 
colored polyhedra in each map surround all lattice points where the QSAR strongly 
associates changes in field values with changes in biological activity, indicating areas 
where appropriate alterations of the field values will enhance or reduce the value of the 
dependent property variable. Color is used to code the direction and magnitude ofthese 
different interactions; CoMF A and CoMSIA models both use the same coloring scheme 
for steric and electrostatic fields. Green polyhedra on a model indicate where increasing 
bulk would lead to a favorable change in a compound's activity (binding is expected to 
increase with increases in steric bulk), while yellow polyhedra indicate where bulk is 
unfavorable. Red polyhedra on a model indicate where increasing charge would lead to a 
favorable change in a compounds activity, while blue polyhedra indicate where charge is 
unfavorable. The colored-coded polyhedra are particularly useful because they allow the 
QSAR maps to easily be interpreted. 
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After a model has been created, the next step is to refine it. The goal of refining a 
model is to maximize the Q2 and R2 values. To do this, major outliers, or compounds with 
large residual values, were deleted. A residual is the difference between the actual and 
predicted activities of a compound. A large residual value indicates that a compound is not 
modeled well by the QSAR and theory predicts that that the expected prediction error for 
such compounds is large. A good method for outlier elimination should ultimately decrease 
the root mean squared error of prediction. However, as few compounds as possible should 
be eliminated. Elimination of prediction outliers leads to substantial improvement of 
prediction errors if extreme outliers are present, but improvement is only modest for 
typical QSAR data sets containing similar compounds. Once major outliers were removed, 
Partial Least Squares QSAR was run again using the modified spreadsheet, generating a 
new and improved model. 
The two uses for QSAR 3-D models are to enable the design of new compounds 
based on examination ofthe displays ofthe CoMFA and CoMSIA results and also to be 
able to predict the target property values of the newly designed compounds. The most 
important characteristic of QSAR models is their predictive power. The predictive power 
of a model indicates how reliable the model is and how well it predicts the activities of 
unknown compounds. To test this, a compound, or several compounds, with a high activity 
were chosen from each dataset and modified according to the information given by the 
model. All of the previously mentioned guidelines were used in constructing and aligning 
them. These new compounds were then added to the corresponding spreadsheet and the 
biological activities of each were predicted using the patterns established from the original 
set of compounds. It was thus determined whether or not the modifications affected the 
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activity in the way that the model indicated. Then, an attempt was made to integrate the 
information learned from each of the models in order to identify the key areas for 
melatonin binding activity and to also make suggestions about structural changes in these 
specific areas that would enhance melatonin's biological activity, as well as decrease its 
side effects. 
III. Results & Discussion 
During this research project, eight different sets of melatonin analogues were 
studied. The compounds outlined in Tables 1- 8 were submitted to comparative molecular 
field analysis (CoMF A) and comparative molecular similarity indices analysis (CoMSIA) 
in order to devise quantitative models for identifying relationships between structural 
features and biological activity. The CoMFA and CoMSIA results for each data set, 
including the predicted activities and residuals, are reported in Tables lA- 8A. 
Set 1 
Set 1 is composed of sixteen 2-substituted indole compounds {Table 1).9 This set 
contained biological activity information about the MT1, MT2, pRA1, and pRA2 binding 
affinities for the indolic analogues. CoMF A/CoMSIA was run on this set of compounds 
four times, using each set ofbinding affinities as the dependent variable once. QSAR 3-D 
models were generated for each CoMF A/CoMSIA run and the results are listed in Table 
1A. 
Although four different sets of numbers were used as the dependent variables, the 
3-D models show nearly identical regions which affected the activity. The maps of steric 
activities indicate that increasing the bulk at the 2-position will enhance activity (Set 1 
figures). They also signify that increasing the bulk at the end of the indolic chain will lead 
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to enhanced activity; however, the models also indicate that past a certain point, bulk will 
become detrimental to the activity of a compound. Electrostatically, the models show a 
region between the indolic chain and the 2-position chain where occupancy of an 
electronegative group enhances activity. The models containing information about both 
sterics and electrostatics reinforce the findings of the separate steric and electrostatic 
models; the field contributions can be seen in the Set 1 models. 
Test compounds were modified according to the insight gained by the 3-D graphs 
and the compounds with their predicted activities are listed in Tables Ia - lh. The most 
successfully modified compounds, according to predicted activities, were those that were 
modified by increasing the charge, and correspondingly the bulk, of the 2-substituted side 
chain in the region indicated by the models. Slightly increasing the bulk of the methoxy 
group to an ethoxy group was also favorable. 
Set 2 
Set 2 consists of a series of sixteen substituted oxygenated heterocycles and thio-
analogues of melatonin (Table 2).13 The ovine pars tuberalis membrane binding affinities 
for these melatonin analogues was used as the dependent variable for the CoMF A and 
CoMSIA analyses; the QSAR results for the models built by PLS analysis are reported in 
Table 2A. 
The CoMF A and CoMSIA analyses indicated similar regions surrounding the side 
chain, close to the ring attachment, where occupancy with sterically demanding groups 
enhances activity (Set 2 figures). The 3-D maps containing electrostatic property 
information also show areas, at the beginning and towards the end, on the side chain where 
increased electronegative groups enhance activity. A region to be avoided by 
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electronegative groups is indicated at the end of the methoxy group, while a yellow 
polyhedron to the left of the oxygen on the methoxy group shows a region to be avoided by 
sterically demanding groups. 
Test compounds were built in accordance with the information displayed by the 
CoMF A and CoMSIA 3-D maps and the activities for each were predicted (Tables 2a-
2c). The initial activities ofthe substituted oxygenated heterocycles and thio-analogues of 
melatonin were all lower than that ofunmodified melatonin and although the predicted 
activities increased for the modified test compounds, they still did not surpass the binding 
affinity of melatonin. Increasing the charge towards the end of the side chain and 
increasing the bulk towards the beginning of the side chain led to the most successfully 
modified compounds according to predicted activities. 
Set3 
Set 3 contains a series of forty-six naphthalenic analogues of melatonin (Table 3).21 
The original series was composed of fifty derivatives, but binding studies only provided 
useful1-state (site) model receptor binding information for forty-six ofthe compounds.21 
The compounds were analyzed as a global set, and then three subsets were analyzed 
individually. The three subsets were composed of compounds 10-38, 10-47, and 48-60. 
Comparable results were obtained for all four runs; the QSAR results for the models built 
by PLS analysis using ovine pars tuberalis membrane binding affmities as the dependent 
variable are reported in Table 3A. 
The CoMFA and CoMSIA 3-D maps for all four runs had a red region surrounding 
the oxygen ofthe methoxy group, signifying its importance in binding activity (Set 3 
figures) . Sterically, green polyhedra indicated that increasing the length ofthe methoxy 
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group would be beneficial. While the 3-D graphs showed that adding bulk to the side chain 
can increase binding affinity, predicted activities indicate that additional bulk is only 
beneficial to a certain point and then it becomes detrimental. Key areas for adding 
electronegative elements to the side chain were also identified. 
Test compounds were modified according to the insight gained by the 3-D graphs 
and the compounds with their predicted activities are listed in Tables 3a - 3e. The test 
compounds with the most favorable increase in predicted activities were those modified by 
changing the methoxy group to either an ethoxy or isopropoxy group. 
Set 4 
Set 4 includes a series of twenty-seven benzocycloalkene derivatives using indan, 
tetraline, and benzocycloheptene as the base structures (Table 4).5 Human MT1 and 
hamster MT 3 binding affinities were used as the dependent variables for CoMF A and 
CoMSIA analyses (Table 4A).5 
The CoMF A and CoMSIA steric analyses using the human MT 1 binding affmities 
indicate that increasing the length of the methoxy chain will result in a favorable increase 
in binding affinity. The MT1 3-D maps also show regions along the side chain where 
increasing the sterics and the charge will enhance binding affmity (Set 4 MT1 figures). 
However, they indicate that increasing the length ofthe side chain will result in a loss of 
binding affmity. 
The hamster MT 3 CoMSIA and CoMF A results are very similar to the MT 1 maps. 
The MT3 3-D maps also indicate that increasing the length of the methoxy chain will result 
in increased binding affinity (Set 4 MT 3 figures). Additionally, a green polyhedron on the 
CoMSIA 3-D map indicates that increasing the bulk at the indolic nitrogen would be 
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beneficial. The electrostatic map and the map containing both static and electrostatic MT 3 
information show that an increase of charge in a region around the ester group will result in 
a favorable increase in binding affmity. 
Test compounds were built in an attempt to maximize binding potential based on 
the CoMF A/CoMSIA indicators and the predicted activities are reported in Tables 4a - 4c. 
The most successfully modified compounds, according to the predicted activities for both 
MT 1 and MT 3, were those modified by changing the methoxy group to either an ethoxy or 
propoxy group. The MT3 test compounds with bulk added to the indolic nitrogen had 
favorable increases in predicted binding affinity as well. 
SetS 
Set 5 is made up of a series of thirty-five N-naphthylethyl amide derivatives (Table 
5).18 These compounds were previously synthesized and evaluated as melatonin receptor 
ligands in the hope of designing new compounds which would be metabolically more 
stable than melatonin. 18 Set 5 was evaluated as a global set and then two subsets, each 
containing compounds built from mutual base structures, were analyzed. The ovine pars 
tuberalis membrane binding affmities were used as the dependent variables, and the QSAR 
results for the models created by PLS analysis are listed in Table 5A. 
The CoMFA and CoMSIA analyses ofthese melatonin analogues containing 
steric information indicated two main areas where increasing the bulk has a favorable 
effect on binding affinity (Set 5 figures). These two regions are found at the end ofthe 
methoxy group and the end ofthe side chain. The CoMSIA map created using all ofthe 
compounds and the steric CoMF A map created using compounds 95-105 both showed that 
increasing bulk at the nitrogen on the side chain enhanced binding affmity. Electrostatic 
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polyhedra indicated the importance of the electronegative oxygen in the methoxy group 
and the indolic nitrogen; several regions along the side chain were also identified as 
favorable locations for increased electronegative atoms, particularly toward the end of the 
chain. 
The areas targeted for building modified test compounds, and the ones that gave the 
best results, occur toward the end of the side chain and at the methoxy group. The 
predicted activities for these compounds are reported in Tables Sa - Sf 
Set 6 
Set 6 includes thirty-nine melatonin agonists and antagonists derived from 6H-
isoindolo[2,1-a]indoles, S,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-SH-
benzo[c]azepino[2,1-a]indoles (Table 6i - 6iii). 10 The 6H-isoindolo[2,1-a]indole, 5,6-
dihydroindolo[2, 1-a]isoquinoline, and 6,7-dihydro-SH-benzo[ c ]azepino[2, 1-a]indole 
analogue groups were first analyzed separately and then as a global set. The QSAR results 
for the best models built by PLS analysis using Human MT 1 and MT 2 binding affinities as 
the dependent variables are listed in Table 6A. The Table 6iii subset did not yield 
satisfactory QSAR results, so it was excluded. 
Green polyhedra shown by the CoMF A and CoMSIA results for the MT 1 binding 
affinity analyses indicated that increasing the bulk of the methoxy group would lead to a 
favorable increase in activity; however, the close proximity of a yellow polyhedron limits 
how far the methoxy group can be extended before increased sterics would lead to 
unfavorable changes in binding affmity (Set 6 figures). Another key steric region for MT1 
binding lies to the right ofthe side chain, where increased bulk is shown to be favorable. 
Red polyhedra surrounding the methoxy group indicate the importance ofthe 
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electronegative oxygen atom to binding strength, and other regions along the side chain 
indicate where activity may be enhanced by increasing electronegativity in those areas. 
Several blue regions seen on the MT1 3-D activity maps illustrate where electronegative 
atoms need to be avoided if binding affinity is to be maximized. 
Like the MT1 analyses, MT2 analyses reveal almost identical regions ofsteric and 
electrostatic importance around the methoxy group. The MT 2 CoMSIA and CoMF A 3-D 
maps generated from the global set of compounds contain green polyhedra to the right of 
the side chain in the same location as the MT 1 maps. However, unlike the MT 1 maps, 
multiple blue and yellow polyhedra on the MT 2 maps depict many more areas where care 
must be taken to avoid excess bulk and charge. 
Test compounds were built in an attempt to maximize binding potential based on 
the CoMFA/CoMSIA indicators and the predicted activities are reported in Tables 6a - 61. 
The most successfully modified compounds, according to the predicted activities, were 
those altered by increasing the electronegativity of the R substituent group. 
Set 7 
Set 7 is composed of fifty-six melatonin agonists and antagonists derived from 
tetrahydrocyclopent[b] indo les, tetrahydrocarbazo les, and hexahydrocyc lo hept[b] indo les 
(Table 7). 10 Analysis of the individual subsets did not yield satisfactory results, so the 
compounds shown in the four tables were analyzed together as a global set. Table 7 A lists 
the QSAR results for the models created by PLS analysis. 
Green polyhedra on the 3-D maps containing steric property information indicate 
that increasing the bulk ofthe methoxy group will lead to an increase in activity; they also 
show that increasing the length of the side chain, up to a certain point indicated by a 
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yellow polyhedron, will increase activity (Set 7 figures). The CoMFA map containing 
both electrostatics and sterics indicates that increasing bulk on the indolic nitrogen will 
have a favorable effect. Electrostatically, red polyhedra indicate the importance of the 
oxygen in the methoxy chain, as well as two regions on the side chain where increased 
electronegativity is favorable. 
Test compounds were built in an attempt to maximize binding potential based on 
the CoMFA/CoMSIA indicators, and the predicted activities are reported in Tables 7a-
7b. Adding increased bulk to the indolic nitrogen and changing the methoxy group to an 
ethoxy group led to increased predicted activities of the modified compounds. 
SetS 
Set 8 contains thirty-nine benzoxazole derivatives, which are reported in Table 13.2 
The benzoxazole melatonin analogues were chosen because they possess high binding 
affinity toward human MT 1 and MT 2 receptor subtypes, comparable to or higher than the 
affmity of melatonin itself.2 The QSAR results for the best models built by PLS analysis of 
the global set using Human MT1 and MT2 binding affinities as the dependent variables are 
listed in Table 8A. 
Although the MT2 3-D maps contain more colored polyhedra indicating areas of 
importance, the CoMF A and CoMSIA analyses for both human MT 1 binding affmities and 
MT 2 binding affmities yielded very similar results. Green polyhedra indicate that 
increasing the bulk on the end ofthe R chain will have a favorable effect; the CoMFA 
analyses also show that increasing the bulk on the side ofthe R1 chain toward the end 
should lead to an increase in binding affmity. Electrostatically, red polyhedra indicate the 
importance of the double-bonded oxygen on the R1 chain; in addition, the 3-D maps show 
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an area on the R chain where increasing the electronegativity is favorable for binding 
interaction. 
Test compounds were built in an attempt to maximize binding affinity based on the 
CoMF NCoMSIA indicators and the predicted activities are reported in Tables 8a- 8d. 
Increasing the electronegativity of an atom attached to the ring or increasing the sterics of 
the R1 substituent led to slightly higher predicted activities. 
IV. Conclusions 
The CoMF A and CoMSIA methodology was applied to many structurally different 
melatonin analogues in order to derive 3-D QSAR models correlating the differences in 
biological activity with the variation of the 3-D fields within selected series of compounds. 
For each set of compounds in which the melatonin analogues were grouped, a 3-D QSAR 
model with reasonably good predictive and descriptive power was obtained. The models 
gave useful information about the structure-activity relationships within the eight data sets. 
According to these models, the methoxy group on melatonin is consistently a 
critical component with respect to the strength of its binding affinity. Increasing the sterics 
in this region, such as altering the methoxy group to a larger ethoxy group is predicted to 
correspond with increased activity. The side chain also plays an important role in binding 
affinity; the QSAR results indicate that proper modification of the steric and electrostatic 
properties is key for optimal binding potential. Several of these melatonin analogue sets 
already possess promising melatonin receptor binding affinity initially and, if modified 
according to the QSAR results, may prove to be even more powerful melatonin agonists. 
The models obtained in this study are reasonably predictive and provide useful 
structural information, which can be used to suggest where and how known structures can 
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be modified in order to develop compounds with higher affmity. Additional 3-D 
quantitative structure-activity studies may lead to a better understanding of the molecular 
features required for a compound to exhibit increased melatonergic binding affmity. 
However, further investigation by synthesizing and testing the activity of compounds 
structurally modified in areas according to the information given by the models is needed 
to confirm the reliability ofthese models and the extent of their predictability. 
21 
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Set 1 Human MT 1 Binding 3-D QSAR Maps 
CoMFA (Sterics) 
CoMF A (Both) 
CoMFA (Electrostatics) 
Set 1 Human MT2 Binding 3-D QSAR Maps 
CoMFA (Both) CoMF A (Electrostatics) 
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CoMFA (Sterics) CoMSIA 
Set 1 pRA1 Binding 3-D QSAR Maps 
CoMF A (Both) CoMSIA 
CoMFA (Sterics) 
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Set 1 pRA2 Binding 3-D QSAR Maps 
CoMFA (Sterics) 
CoMF A (Both) 
CoMSIA 
CoMFA (Electrostatics) 
Set 2 Ovine Pars Tuberalis Membrane Binding 3-D QSAR CoMFAb Maps 
CoMF A (Electrostatics) 
CoMF A (Both) 
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CoMFA (Sterics) 
Set 2 Ovine Pars Tuberalis Membrane Binding CoMFAc and CoMSIAd 3-D QSAR Maps 
CoMF A (Both) CoMFA (Sterics) 
CoMF A (Electrostatics) 
CoMSIA 
29 
Set 3 Ovine Pars Tuberalis Membrane Binding 3-D QSAR Maps- All Cmpds 
CoMFA (Sterics) 
CoMF A (Both) 
CoMF A (Electrostatics) 
Set 3 Ovine Pars Tuberalis Membrane Binding 3-D QSAR Maps - Cmpds 10-38 
CoMF A (Both) CoMFA (Electrostatics) 
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CoMFA (Sterics) 
Set 3 Ovine Pars Tuberalis Membrane Binding 3-D QSAR Maps - Cmpds 10-47 
CoMF A (Both) CoMF A (Sterics) 
CoMF A (Electrostatics) 
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Set 3 Ovine Pars Tuberalis Membrane Binding 3-D QSAR Maps - Cmpds 48-60 
CoMFA (Sterics) 
CoMF A (Electrostatics) 
Set 4 Human MT 1 Binding 3-D QSAR Maps 




Set 4 Hamster MT3 Binding 3-D QSAR Maps 
CoMF A (Electrostatics) 
CoMF A (Both) 
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CoMFA (Sterics) CoMSIA 
Set 5 Ovine Pars Tuberalis Membrane Binding 3-D QSAR Maps - All Cmpds 
CoMF A (Both) 
CoMFA (Sterics) 
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Set 5 Ovine Pars Tuberalis Membrane Binding 3-D QSAR Maps - Cmpds 72-94 
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Set 5 Ovine Pars Tuberalis Membrane Binding 3-D QSAR Maps - Cmpds 95-105 
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Set 6 Human MT1 Binding 3-D QSAR Maps - All 
CoMF A (Both) 
CoMF A (Electrostatics) CoMSIA 
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Set 6 Human MTt Binding 3-D QSAR Maps - Table 6ii 
CoMF A (Electrostatics) 
CoMF A (Both) 
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Set 6 Human MT 2 Binding 3-D QSAR Maps - All 
CoMFA (Both) CoMSIA 
CoMFA (Sterics) 
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Set 6 Human MT2 Binding 3-D QSAR Maps - Table 6i 
CoMF A (Both) CoMFA (Sterics) 
CoMFA (Electrostatics) CoMSIA 
Set 6 Human MT2 Binding 3-D QSAR Maps - Table 6ii 
CoMF A (Both) 
CoMF A (Electrostatics) 
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CoMSIA 
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Set 7 Ovine Pars Tuberalis Membrane Binding 3-D QSAR Maps 
CoMF A (Both) 
CoMFA (Sterics) 
CoMFA (Electrostatics) CoMSIA 
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Set 8 Human MT1 Binding 3-D QSAR Maps 
CoMF A (Both) CoMFA (Electrostatics) 
CoMF A (Sterics) CoMSIA 
Set 8 Human MT2 Binding 3-D QSAR Maps 
CoMF A (Both) CoMF A (Electrostatics) 







Table 1 Set I Com2ounds 
bio. act. 
Compound R, MT1 MT2 
cmpdOI COO Me 9.82 10.12 
cmpd02 CF3 9.52 10.08 
cmpd03 S02Me 6.83 7.34 
cmpd04 CHO 8.95 9.34 
cmpd05 CH2CH2Ph 7.20 8.88 
cmpd06 CONH2 7.57 7.79 
cmpd07 NHCONH2 6.65 7.21 
cmpd08 CH20H 7.46 7.87 
cmpd09 H 8.77 9.21 
cmpdlO Ph 9.97 10.36 
cmpdll Br 10.28 10.21 
cmpd12 H 6.93 9.43 
cmpd13 Br 10.54 9.94 
cmpdl4 Ph 10.66 10.42 
cmpd15 10.64 10.29 
cmpd16 CH2Ph 7.50 9.60 
Test Original Modification( s) 
cmpd17 cmpdl4 OCH3 
cmpdl8 cmpdl4 naphthalene 
cmpd19 cmpdl3 N-NH2 
cmpd20 cmpdl3 CH2-Br 
cmpd21 cmpdl3 C(CH3h-Br 
cmpd22 cmpdl5 CHrl 
cmpd23 cmpd16 CH-BrPh 
cmpd24 cmpdl3 C(Brh 
cmpd25 cmpdl6 C(Br)2Ph 
cmpd26 cmpdl6 OCH3 
cmpd27 cmpd02 CH2CF3 
cmpd28 cmpd02 Cul10H 
cmpd29 cmpd02 c'~CH3 
cmpd30 cmpd02 CBr3, OCH2CH2Br 
cmpd31 cmpd02 CBr3, OCH2CH3 
cmpd32 cmpdlO OCH3 
cmpd33 cmpdlO C13HCH2CH3 
cmpd34 cmpdlO OCH(CH3h 
cmpd35 cmpdll CH2CH2CBr3 




Set 1: Summary of the Statistical Results for the PLS Analyses 9,. 
HumanMT1 Human MT2 
CoMFAb CoMSIA CoMFAc CoMSIA 
B E s B E s 
Q2 0.462 0.411 0.406 0.455 0.584 0.468 0.134 0.684 
no. comp 5 6 3 2 4 6 
s 0.694 0.684 0.222 0.062 0.177 0.340 0.214 0.091 
R2 0.801 0.807 0.987 0.999 0.979 0.915 0.973 0.996 
F 44.350 45.936 106.449 1388.633 141.605 53.655 71.657 374.138 
Prob. R2=0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
pRAt pRA2 
CoM FAd CoMSIA CoMFAe CoMSIA 
B E s B E s 
Q2 0.257 -0.021 0.421 0.646 0.298 0.227 0.321 0.758 
no. comp 3 4 6 3 3 6 
s 0.313 0.730 0.271 0.087 0.282 0.591 0.302 0.067 
R2 0.938 0.596 0.958 0.996 0.938 0.675 0.929 0.997 
F 50.624 17.712 51.602 418.412 50.694 24.977 43.833 577.121 
Prob. R2=0 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 
• Alignment using MLT as the basic molecule b Outliers: I, 8,16 c Outliers: I, 6, 8 d Outliers: 8, II c Outliers: 8, II 
Table la CoMF A Human MTl 
MT1 PAB RESB PAE RESE PAS RESS 
CMPD02 (5B) 9.52 9.44 0.08 9.24 0.28 9.30 0.22 
CMPD03 (5C) 6.83 5.75 1.08 6.15 0.68 6.84 -0.01 
CMPD04 (5D) 8.95 8.82 0.13 8.46 0.49 9.28 -0.33 
CMPD05 (5E) 7.20 7.89 -0.69 7.88 -0.68 7.21 -0.01 
CMPD06 (5F) 7.57 8.28 -0.71 8.06 -0.49 7.57 0.00 
CMPD07 (5G) 6.65 7.55 -0.90 7.47 -0.82 6.63 0.03 
CMPD09 (51) 8.77 9.47 -0.70 9.43 -0.66 8.95 -0.18 
CMPD10 (5J) 9.97 9.72 0.25 10.22 -0.25 9.80 0.17 
CMPD11 10.28 9.58 0.70 9.18 1.10 10.20 0.08 
CMPD12 9.63 10.35 -0.72 10.44 -0.8 1 9.57 0.06 
CMPD13 10.54 9.96 0.58 9.90 0.64 10.28 0.26 
CMPD14 10.66 10.18 0.48 10.59 0.07 10.84 -0.18 
CMPD15 10.64 10.22 0.43 10.20 0.44 10.76 -0.12 
43 
Table la CoMF A Human MTI coot 
Modified PAB ll PAE ll PAS ll 
CMPD17 ? 10.11 -0.07 10.33 -0.25 10.78 -0.06 
CMPD18 ? 9.57 -0.61 9.67 -0.91 9.45 -1.39 
CMPD19 ? 10.28 0.32 9.83 -0.06 10.65 0.38 
CMPD20 ? 10.13 0.17 10.48 0.58 9.90 -0.94 
CMPD21 ? 9.79 -0.17 9.95 0.05 9.39 -1.38 
CMPD22 ? 10.36 0.14 10.25 0.05 11.66 0.89 
CMPD23 ? 9.93 0.86 10.47 1.58 10.02 1.13 
CMPD24 ? 9.46 -0.50 9.95 0.05 9.07 -0.39 
CMPD25 ? 9.76 0.68 10.21 1.32 9.96 1.07 
CMPD26 ? 9.67 0.60 9.78 0.89 9.94 1.05 
CMPD27 ? 9.36 -0.08 9.29 0.05 9.44 0.14 
CMPD28 ? 8.57 -0.87 8.38 -0.86 8.64 -0.66 
CMPD29 ? 9.50 0.05 9.36 0.12 9.40 0.10 
CMPD30 ? 9.67 0.22 9.74 0.49 10.01 0.71 
CMPD31 ? 9.47 0.02 9.51 0.27 9.43 0.13 
CMPD32 ? 9.52 -0.20 9.44 -0.79 9.44 -0.36 
CMPD33 ? 9.27 -0.44 9.80 -0.42 10.17 0.37 
CMPD34 ? 9.38 -0.34 9.41 -0.81 10.56 0.76 
Table 1 b CoMSIA Human MT 1 Table lb CoMSIA Human MT 1 
MTI PA RES Modified PA ll 
CMPD01 (SA) 9.82 9.85 -0.03 CMPD17 ? 10.19 -0.43 
CMPD02 (5B) 9.52 9.51 0.01 CMPD18 ? 9.02 -1.60 
CMPD03 (5C) 6.83 6.83 0.00 CMPD19 ? 9.34 -1.29 
CMPD04 (5D) 8.95 8.94 O.Ql CMPD20 ? 9.92 -0.72 
CMPD05 (5E) 7.20 7.22 -0.02 CMPD21 ? 9.33 -1.31 
CMPD06(5F) 7.57 7.54 0.03 CMPD22 ? 9.61 -0.91 
CMPD07 (5G) 6.65 6.65 0.00 CMPD23 ? 8.61 1.11 
CMPD08 (5H) 7.46 7.44 0.02 CMPD24 ? 10.50 -0.14 
CMPD09 (51) 8.77 8.79 -0.02 CMPD25 ? 9.20 1.70 
CMPD10 (5J) 9.97 10.00 -0.03 CMPD26 ? 8.90 1.40 
CMPD11 (5K) 10.28 10.25 0.03 CMPD27 ? 8.59 -0.93 
CMPD12 9.63 9.70 -0.06 CMPD28 ? 10.02 0.51 
CMPD13 10.54 10.64 -0.10 CMPD29 ? 9.62 0.11 
CMPD14 10.66 10.62 0.04 CMPD30 ? 9.77 0.25 
CMPD15 10.64 10.52 0.12 CMPD31 ? 9.69 0.17 
CMPD16 7.50 7.50 0.00 CMPD32 ? 9.26 -0.74 
CMPD33 ? 10.11 0.11 
CMPD34 ? 10.00 0.00 
44 
Table lc Set 1 CoMF A Human MT2 
EA PABRESB PAERESE PAS RESS 
CMPD02 (5B) 10.08 9.99 0.09 9.78 0.30 10.01 0.07 
CMPD03 (5C) 7.34 7.36 -0.02 7.33 0.01 7.37 -0.03 
CMPD04 (5D) 9.34 9.57 -0.23 9.10 0.24 9.72 -0.38 
CMPD05 (5E) 8.88 8.70 0.18 9.20 -0.32 8.90 -0.02 
CMPD07 (5G) 7.21 7.20 0.01 7.49 -0.28 7.07 0.14 
CMPD09 (51) 9.21 9.26 -0.05 9.22 -0.01 9.37 -0.16 
CMPD10 (5J) 10.36 10.40 -0.04 10.94 -0.58 10.31 0.05 
CMPDll (5K) 10.21 10.19 0.02 10.02 0.19 10.13 0.08 
CMPD12 9.43 9.76 -0.33 9.84 -0.41 9.57 -0.14 
CMPD13 9.94 9.96 -0.02 9.88 0.06 9.75 0.19 
CMPD14 10.42 10.34 0.08 10.31 0.11 10.31 0.11 
CMPD15 10.29 10.03 0.26 9.82 0.47 10.04 0.26 
CMPD16 9.60 9.56 0.04 9.37 0.23 9.78 -0.18 
Modified PAB 11 PAE 11 PAS 11 
CMPD17 ? 10.24 -0.10 10.15 -0.16 10.29 -0.02 
CMPD18 ? 10.13 -0.21 9.87 -0.45 9.5 1 -0.81 
CMPD19 ? 9.98 0.02 9.66 -0.22 10.34 0.58 
CMPD20 ? 10.22 0.26 10.41 0.53 10.06 0.31 
CMPD21 ? 10.15 0.19 10.22 0.34 9.55 -0.20 
CMPD22 ? 10.39 0.36 9.98 0.16 10.91 0.88 
CMPD23 ? 9.82 0.26 9.88 0.50 9.80 0.02 
CMPD24 ? 9.76 -0.20 9.89 0.02 9.52 -0.23 
CMPD25 ? 9.81 0.24 9.69 0.31 9.91 0.13 
CMPD26 ? 9.75 0.19 9.42 0.04 9.92 0.14 
CMPD27 ? 10.07 0.07 10.03 0.25 9.72 -0.29 
CMPD28 ? 9.78 -0.21 9.78 0.00 9.44 -0.57 
CMPD29 ? 9.91 -0.09 9.91 0.13 10.12 0.11 
CMPD30 ? 10.01 0.01 10.21 0.43 10.13 0.11 
CMPD31 ? 9.74 -0.25 9.80 0.02 9.82 -0.19 
CMPD32 ? 10.38 -0.02 10.20 -0.73 10.08 -0.23 
CMPD33 ? 10.01 -0.39 10.66 -0.28 10.33 0.02 
CMPD34 ? 10.14 -0.26 10.47 -0.47 10.58 0.27 
CMPD35 ? 10.31 -0.09 10.64 -0.30 10.32 0.02 
CMPD36 ? 10.46 0.06 10.85 -0.09 10.51 0.20 
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Table ld Set 1 CoMSIA Human MT2 
EA PA RES 
CMPDOI (SA) 10.12 10.15 -0.03 
CMPD02 (SB) 10.08 10.11 -0.03 
CMPD03 (SC) 7.34 7.36 -0.02 
CMPD04 (SD) 9.34 9.31 0.03 
CMPD05 (SE) 8.88 8.88 0.00 
CMPD06(5F) 7.79 7.75 0.04 
CMPD07 (5G) 7.21 7.18 0.03 
CMPD07 (SH) 7.87 7.89 -0.02 
CMPD09 (51) 9.21 9.22 -0.01 
CMPD10 (5J) 10.36 10.34 0.02 
CMPDll (5K) 10.21 10.24 -0.03 
CMPD12 9.43 9.50 -0.07 
CMPD13 9.94 10.06 -0.12 
CMPD14 10.42 10.37 0.06 
CMPD15 10.29 10.08 0.21 
CMPD16 9.60 9.65 -0.05 
Modified PA A 
CMPD17 ? 10.36 0.00 
CMPD18 ? 10.06 -0.30 
CMPD19 ? 9.92 -0.14 
CMPD20 ? 9.78 -0.28 
CMPD21 ? 9.56 -0.50 
CMPD22 ? 9.76 -0.32 
CMPD23 ? 10.10 0.46 
CMPD24 ? 10.30 0.24 
CMPD25 ? 10.55 0.90 
CMPD26 ? 10.59 0.94 
CMPD27 ? 9.46 -0.65 
CMPD28 ? 10.21 0.10 
CMPD29 ? 10.27 0.15 
CMPD30 ? 10.51 0.40 
CMPD31 ? 10.32 0.21 
CMPD32 ? 10.11 -0.23 
CMPD33 ? 10.45 0.12 
CMPD34 ? 10.35 0.02 
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Table le Set 1 CoMFApRA1 
EA PAB RESB PAE RESE PAS RESS 
CMPD01 (SA) 0.82 0.72 0.10 0.05 0.77 0.80 0.02 
CMPD02 (5B) 1.34 1.18 0.16 0.18 1.16 1.29 0.05 
CMPD03 (5C) -1.54 -1.56 0.02 -2.11 0.56 -1.47 -0.07 
CMPD04(5D) 0.02 0.48 -0.46 -0.45 0.47 0.50 -0.48 
CMPD05 (5E) -1.24 -1.10 -0.14 -1.00 -0.24 -1.26 0.02 
CMPD06 (5F) -1.71 -1.66 -0.05 -0.98 -0.73 -1.63 -0.08 
CMPD07 (5G) -1.95 -2.21 0.26 -1.01 -0.94 -2.18 0.23 
CMPD09 (51) 0.05 0.18 -0.13 0.14 -0.09 0.28 -0.23 
CMPDIO (5J) 0.04 0.11 -0.07 0.07 -0.03 -0.05 0.09 
CMPD12 0.05 0.52 -0.47 0.84 -0.79 0.10 -0.05 
CMPD13 1.26 0.75 0.51 0.49 0.77 0.75 0.51 
CMPD14 0.04 0.18 -0.14 0.67 -0.63 0.11 -0.07 
CMPD15 1.15 0.82 0.33 0.66 0.49 1.00 0.15 
CMPD16 -0.31 -0.40 0.09 0.46 -0.77 -0.20 -0.11 
Modified PAB !1 !1 !1 
CMPD19 ? 0.86 0.11 0.47 -0.02 0.97 0.22 
CMPD20 ? 0.80 0.05 0.83 0.33 1.15 0.40 
CMPD21 ? 0.35 -0.41 0.42 -0.07 0.31 -0.44 
CMPD22 ? 0.73 -0.09 0.68 0.01 1.29 0.29 
CMPD23 ? 0.02 0.42 0.80 0.34 0.21 0.41 
CMPD24 ? 0.46 -0.29 0.56 0.06 0.32 -0.43 
CMPD25 ? -0.04 0.36 0.66 0.20 -0.15 0.05 
CMPD26 ? -0.01 0.39 0.47 0.01 -0.18 0.02 
CMPD27 ? -0.03 -1.21 -0.07 -0.25 0.40 -0.89 
CMPD28 ? -0.13 -1.32 -0.78 -0.97 -0.01 -1.31 
CMPD29 ? 1.17 -0.02 0.25 0.07 1.32 0.02 
CMPD30 ? 0.91 -0.27 0.42 0.24 1.25 -0.04 
CMPD31 ? 0.41 -0.77 0.21 0.03 0.89 -0.40 
Table 1f Set 1 CoMSIA pRA1 
EA PA RES 
CMPDOI (5A) 0.82 0.91 -0.09 
CMPD02 (5B) 1.34 1.26 0.08 
CMPD03 (5C) -1.54 -1.54 -0.01 
CMPD04 (5D) 0.02 -0.06 0.08 
CMPD05 (5E) -1.24 -1 .238 0.00 
CMPD06 (5F) -1.71 -1.77 0.06 
CMPD07 (5G) -1.95 -1.92 -0.03 
CMPD08 -1.35 -1.39 0.04 
CMPD09 (51) 0.05 0.14 -0.09 
CMPDIO (5J) 0.04 0.02 0.02 
CMPDll (5K) 1.26 1.31 -0.05 
CMPD12 0.05 0.15 -0.10 
CMPD13 1.26 1.24 0.02 
CMPD1 4 0.04 0.05 -0.01 
CMPD15 1.15 1.02 0.13 
CMPD16 -0.31 -0.25 -0.06 
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Table lg Set 1 CoMFApRA2 
EA PAB RESB PAE RESE PAS RESS 
CMPD01 0.49 0.41 0.09 -0.18 0.67 0.47 0.02 
CMPD02 (5B) 1.09 0.94 0.15 0.20 0.89 0.95 0.14 
CMPD03 (5C) -1.65 -1.67 0.02 -1.99 0.34 -1.67 0.02 
CMPD04(5D) -0.25 0.18 -0.43 -0.44 0.19 0.15 -0.40 
CMPD05 (5E) -0.16 0.01 -0.17 -0.34 0.17 -0.03 -0.13 
CMPD06 (SF) -1.69 -1.61 -0.08 -0.76 -0.93 -1.64 -0.05 
CMPD07 (5G) -1.75 -1.97 0.22 -1.06 -0.69 -1.88 0.12 
CMPD09 (51)" O.ot 0.11 -0.10 0.24 -0.23 0.11 -0.10 
CMPD10 (5J) 0.52 0.43 0.09 0.39 0.13 0.60 -0.08 
CMPD12 0.01 0.509. -0.50 0.90 -0.89 0.15 -0.14 
CMPD13 1.03 0.64 0.39 0.50 0.53 0.34 0.69 
CMPD14 0.52 0.54 -0.02 0.79 -0.27 0.83 -0.31 
CMPD15 1.04 0.78 0.26 0.68 0.36 0.75 0.29 
CMPD16 0.32 0.23 0.09 0.60 -0.28 0.38 -0.06 
Modified PAB ti PAE ti PAS ti 
CMPD19 ? 0.81 0.17 0.56 0.06 0.90 0.55 
CMPD20 ? 0.78 0.14 0.85 0.35 0.79 0.45 
CMPD21 ? 0.60 -0.04 0.45 -0.05 0.37 0.03 
CMPD22 ? 0.75 -0.04 0.70 0.02 1.30 0.55 
CMPD23 ? 0.44 0.21 0.81 0.21 0.58 0.19 
CMPD24 ? 0.56 -0.09 0.48 -0.02 0.32 -0.02 
CMPD25 ? 0.47 0.24 0.68 0.08 0.48 0.10 
CMPD26 ? 0.51 0.28 0.48 -0.12 0.48 0.09 
CMPD27 ? 0.09 -0.85 0.08 -0.12 0.28 -0.67 
CMPD28 ? -0.23 -1.17 -0.51 -0.71 -0.34 -1.29 
CMPD29 ? 0.95 O.ot 0.27 0.07 1.04 0.09 
CMPD30 ? 0.92 -0.02 0.43 0.24 1.14 0.19 
CMPD3 1 ? 0.49 -0.44 0.25 0.05 0.84 -0.11 
Table lh Set I CoMSIA pRA2 
EA PA RES 
CMPD01 0.49 0.54 -0.04 
CMPD02 (5B) 1.09 1.08 0.01 
CMPD03 (5C) -1.65 -1.62 -0.03 
CMPD04 (5D) -0.25 -0.31 0.06 
CMPD05 (5E) -0.16 -0.15 -0.01 
CMPD06 (5F) -1.69 -1.71 0.02 
CMPD07 (5G) -1.75 -1.79 0.04 
CMPD08 (5H) -1.26 -1.24 -0.02 
CMPD09 (51) 0.01 0.05 -0.04 
CMPD10 (5J) 0.52 0.47 0.05 
CMPD11 (5K) 1.03 1.08 -0.05 
CMPD12 0.01 0.07 -0.06 
CMPDl3 1.03 1.03 0.00 
CMPD14 0.52 0.50 0.02 
CMPD15 1.04 0.92 0.12 
CMPD16 0.32 0.39 -0.07 
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Table 2 Set 2 Co!!!£ounds 
Compound u v 
cmpdOI 
cmpd02 CH2 0 
cmpd03 CH2 0 
cmpd04 CH2 0 
cmpd05 CH2 0 
cmpd06 CH2 0 
cmpd07 CH2 s 
cmpd08 CH2 s 
cmpd09 CH2 s 
cmpdlO CH2 0 
cmpdll CH2 0 
cmpd12 0 0 
cmpd13 0 0 
cmpdl4 0 0 
cmpdl5 0 0 
cmpdl6 0 s 
Test Original 
cmpdl7 cmpd04 
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Set 2: Summary of the Statistical Results for the PLS Analyses 13.a 
Ovine Pars Tuberalis Membrane Binding 
CoMFAb CoMFAc CoMSIAd 
B E s B E s 
Q2 0.390 0.253 0.395 0.406 0.197 0.545 0.471 
no. comp 4 2 2 6 2 6 6 
s 0.130 0.292 0.317 0.064 0.314 0.023 0.129 
R2 0.994 0.963 0.956 0.999 0.959 1.000 0.994 
F 339.936 130.066 109.371 896.319 105.535 6769.902 229.905 
Prob. R2=0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
• Alignment using MLT as the basic molecule b Outliers: 2, 9, 13 <outliers: 2, 9, 12, 13 d Outlier: 2 
Table 2a Set 2 Predicted Activities: CoMFAb 
EA PAB RESB PAE RESE PAS RESS 
CMPDO I (ML T) 9.52 9.56 -0.04 9.34 0.18 9.37 0.15 
CMPD03 (1 B) 6.62 6.58 0.04 6.80 -0.18 6.93 -0.31 
CMPD04 (1 CA) 7.11 7.05 0.06 7.00 O.II 6.77 0.34 
CMPD05 (1CB) 7.46 7.33 0.13 7.34 0.12 7.59 -0.13 
CMPD06 (1 D) 7.12 7.23 -0.11 7.28 -0.16 6.98 0.14 
CMPD07 (1 E) 7.02 6.95 0.07 6.99 0.03 6.64 0.38 
CMPD08 {1 F) 7.14 7.20 -0.06 7.16 -0.02 6.90 0.24 
CMPD10 (1HA) 7.20 7.21 -0.01 7.31 -0.11 7.27 -0.07 
CMPD11 (I HB) 7.48 7.46 0.02 7.7I -0.23 8.10 -0.62 
CMPD12 (I1) 5.60 5.75 -0.15 5.32 0.28 5.64 -0.04 
CMPD14 (1 K) 6.05 6.06 -0.01 5.85 0.20 5.81 0.24 
CMPD15 (1 L) 4.68 4.47 0.21 4.29 0.39 4.72 -0.04 
CMPDI6 {IM} 4.00 4.15 -0.15 4.63 -0.63 4.29 -0.29 
Modified EA PAB 1:1 PAE 1:1 PAS 1:1 
CMPDI7 ? 7.00 -0.05 6.90 -0.10 6.84 0.07 
CMPD18 ? 7.30 0.25 6.61 -0.39 7.38 0.6I 
CMPD19 ? 7.34 0.29 7.23 0.23 6.82 0.05 
CMPD20 ? 6.68 -0.36 8.57 1.57 6.29 -0.48 
CMPD21 ? 6.96 -0.09 8.68 1.68 6.38 -0.39 
CMPD22 ? 7.45 O.I2 7.51 0.1 7 7.54 -0.05 
CMPD23 ? 6.71 -0.34 7.16 0.16 6.79 0.02 
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Table 2b Set 2 Predicted Activities: CoMF A c 
EA PAB RESB PAE RESE PAS RESS 
CMPDOI (MLT) 9.52 9.53 -0.01 9.44 0.08 9.52 0.00 
CMPD03 (1B) 6.62 6.61 0.01 6.87 -0.25 6.62 0.00 
CMPD04 (ICA) 7.I1 7.16 -0.05 6.94 0.17 7.10 0.01 
CMPD05 (ICB) 7.46 7.47 -0.01 7.26 0.20 7.47 -O.OI 
CMPD06 (lD) 7.12 7.18 -0.06 7.31 -0.19 7.15 -0.03 
CMPD07 (IE) 7.02 6.98 0.04 6.99 0.03 7.03 -O.OI 
CMPD08 (IF) 7.I4 7.07 0.07 7.18 -0.04 7.11 0.03 
CMPDIO (1HA) 7.20 7.2I -0.01 7.24 -0.04 7.2I -O.OI 
CMPDI I (IHB) 7.48 7.46 0.02 7.61 -0.13 7.48 0.00 
CMPDI4 (lK) 6.05 6.05 0.00 5.64 0.4I 6.05 0.00 
CMPD15 (1L) 4.68 4.62 0.06 4.30 0.38 4.70 -0.02 
CMPD16~1M) 4.00 4.06 -0.06 4.62 -0.62 3.99 0.01 
Modified EA PAB 6. PAE 6. PAS 6. 
CMPD17 ? 7.16 0.00 6.88 -0.06 7.27 O.I7 
CMPD18 ? 7.42 0.26 6.62 -0.32 7.69 0.59 
CMPDI9 ? 7.33 0.17 7.21 0.27 6.94 -0.17 
CMPD20 ? 6.40 -0.77 8.36 1.42 5.88 -1.22 
CMPD21 ? 6.66 -0.50 8.52 1.58 6.08 -1.02 
CMPD22 ? 7.33 -0.15 7.24 -0.02 7.I8 -0.28 
CMPD23 ? 6.84 -0.32 7.15 0.2I 7.13 0.02 
Table 2c Set 2 Predicted Activities: CoMSIA 
EA PA RES 
CMPDOI (MLT) 9.52 9.53 -0.01 
CMPD03 (IB) 6.62 6.58 0.04 
CMPD04 (1CA) 7.11 7.22 -O.I1 
CMPD05 (1CB) 7.46 7.52 -0.06 
CMPD06 (lD) 7.12 7.25 -0.13 
CMPD07 (IE) 7.02 6.97 0.05 
CMPD08 (IF) 7.14 7.00 0.14 
CMPD09 (IG) 6.66 6.66 0.00 
CMPDIO (IHA) 7.20 7.14 0.06 
CMPD11 (1HB) 7.48 7.44 0.04 
CMPD12 (11) 5.60 5.61 -0.01 
CMPD13 (1J) 6.45 6.44 0.01 
CMPD14 (1K) 6.05 6.08 -0.03 
CMPD15 (1 L) 4.68 4.49 0.19 
CMPD16 (1M2 4.00 4.19 -0.19 
Modified EA PA 6. 
CMPD17 ? 7.27 0.05 
CMPD18 ? 6.48 -0.74 
CMPD19 ? 6.23 -0.99 
CMPD20 ? 6.60 -0.62 
CMPD21 ? 6.38 -0.84 
CMPD22 ? 6.61 -0.91 
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Table 3 Set 3 Compounds 
Compound Rl R2 n X R bio. act. 
cmpd01 OCH3 H NH CH3 9.57 
cmpd10 H H 0 CH3 8.40 
cmpd11 H H 0 CJHs 7.38 
cmpd12 H H 0 C4H7 7.40 
cmpd13 H H 0 CF3 7.18 
cmpd14 H H 0 CHrC6Hs 5.67 
cmpd15 H H 0 (CH2)3CJis 5.84 
cmpd16 H COOCH3 0 C3Hs 6.04 
cmpd17 H COOCH3 0 C4H7 5.16 
cmpd18 OCH3 H 0 0 CH3 6.34 
cmpd19 OCH3 H 2 0 CH3 8.34 
cmpd20 OCH3 H 2 0 nC~9 6.71 
cmpd21 OCH3 H 2 0 CJHs 7.62 
cmpd22 OCH3 H 0 OCH3 7.72 
cmpd24 OCH3 H 0 NH2 8.45 
cmpd25 OCH3 H 1 0 NHCH3 8.66 
cmpd26 OCH3 H 1 0 NHC2Hs 8.17 
cmpd28 OCH3 H 1 0 NHnC~9 5.61 
cmpd29 OCH3 H 1 0 NHCH2CH2MN 5.92 
cmpd30 H H 0 NH2 6.62 
cmpd31 H H 1 0 NHCH3 6.97 
cmpd32 OCH3 H 0 0 NHnC3H7 7.28 
cmpd33 OCH3 H 0 0 NHnC4H9 5.70 
cmpd34 OCH3 H 2 0 NHnC3H7 6.79 
NH 




Table 3 Set 3 Compounds cont. 
Compound R, Rz n X R bio. act. 
cmpd35 OCH3 H s NHCH3 8.05 
cmpd38 OCH3 H I s NHnC4H9 5.44 
cmpd39 2 CH3 5.94 
cmpd40 2 CzHs 6.09 
cmpd41 3 COCH3 6.70 
cmpd42 2 COCH3 6.16 
cmpd43 2 H 6.36 
cmpd44 2 CH3 8.15 
cmpd45 3 CH3 8.29 
cmpd46 3 nC3H7 7.37 
cmpd47 1 CH2CH2CH2C6Hs 7.16 
cmpd48 H NH nC4H9 5.60 
cmpd49 H NH C3Hs 6.81 
cmpd50 H NH C4H7 5.65 
cmpd51 H NH Cs~ 5.57 
cmpd53 OCH3 NH NHCH2CH2MI 6.40 
cmpd54 OCH3 0 NHCH3 8.22 
cmpd55 OCH3 0 NHC2H5 8.37 
cmpd56 OCH3 0 NHnC3H7 7.33 
cmpd57 H 0 C4H7 5.80 
cmpd59 H s C3Hs 7.53 
cmpd60 H s C4H7 6.27 
Test Original Modification{ s} 
cmpd61 cmpd19 n=3 
cmpd62 cmpdl9 OCH2CH3 
cmpd63 cmpd20 n=3 
cmpd64 cmpd21 n=3 
cmpd65 cmpd25 OCH2CH3 
cmpd66 cmpd10 OCH3 
cmpd67 cmpdlO OCH2CH3 
cmpd68 cmpd23 R=NHnC3H7 
cmpd130 cmpd55 cJ'H2F 
cmpd131 cmpd55 C11Fr 
cmpdl32 cmpd55 NHCH(CH3)z 
cmpd133 cmpd55 OCH2CH3 
cmpdl34 cmpd55 OCH(CH3h 
cmpdl35 cmpd01 C 14H2F 
cmpd136 cmpdOl C 14H2F 
cmpd137 cmpdOJ OCH2CH3 
crnpdl38 cmpdOl OCH(CH3h 
cmpdl39 cmpd24 NHCH3 
cmpd140 cmpd24 OCH2CH3 
cmpd141 cmpd24 OCH(CH3)z 
cmpd142 cmpd35 C6H2F 
cmpdl43 c~d35 OCH2CH3 
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Table 3 Set 3 Compounds cont. 
Test Original Modification( s) 
cmpd44 cmpd35 OCH(CH3)2 
cmpdl45 cmpd25 d~2CH3 
cmpd146 cmpd25 replace =0 with F 
cmpd147 cmpd25 OCH2CH3 
cmpdl48 cmpdl9 c•2HzF 
cmpd149 cmpdl9 OCH2CH3 
cmpd150 cmpd25 OCH(CH3)2 
cmpd151 cmpd25 OC(CH3)3 
cmpd152 cmpd25 OCH(CH3)2 
cmpdl53 cmpdl9 OCH(CH3)2 
cmpdl54 cmpd54 OCH2CH3 
cmpdl55 cmpd54 OCH2CH3, C16HzF 
• MLT b MN: 7-Methoxy-1-naphthyl c Ml: 5-Methoxy-3-indolyl 
Table3A 
Set 3: Summary of the Statistical Results for the PLS Analyses 21 ·" 
Ovine Pars Tuberalis Membrane Binding 
All All Cmpds 10-38 
CoMFAb CoMSIAc CoMFAd 
B E s B E s 
Q2 0.548 0.420 0.399 0.621 0.689 0.657 0.631 
no. comp 6 2 5 4 6 6 6 
s 0.202 0.599 0.326 0.413 0.074 0.106 0.120 
Rz 0.972 0.721 0.924 0.882 0.997 0.993 0.991 
F 184.638 46.621 80.469 59.861 698.533 338.734 259.474 
Prob. R2=0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cmpds 10-47 Cmpds 48-60 
CoMFA• CoMFAr 
B E s B E s 
Q2 0.651 0.379 0.547 0.679 0.545 0.660 
no. comp 6 6 5 3 6 2 
s 0.128 0.214 0.266 0.282 0.138 0.000 
R2 0.987 0.963 0.940 0.970 0.996 1.000 
F 276.302 95.567 72.480 63.715 135.907 
Prob. R2=0 0.000 0.000 0.000 0.000 0.001 
• Alignment using cmpdl8 as the basic molecule b Oulliers: 10, II , 12, 15, 32, 44,59 'Outliers: 10, 11, 12, 15, 30, 32, 41 , 44,59 d Oulliers: 
10, 24, 30, 31 'Outliers: I 0, 24, 30, 31, 44 f Outliers: 55, 59 
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Table 3a Set 3 CoMF A All 
EA PAB RESB 
CMPD01 9.57 9.54 0.03 
CMPDI3 7.18 7.01 0.17 
CMPDI4 5.67 5.50 0.17 
CMPD16 6.04 6.15 -0.11 
CMPD17 5.16 4.92 0.24 
CMPDI8 6.34 6.19 0.15 
CMPDI9 8.34 8.25 0.09 
CMPD20 6.71 7.01 -0.30 
CMPD21 7.62 7.52 0.10 
CMPD22 7.72 7.86 -0.14 
CMPD24 8.45 8.26 0.19 
CMPD25 8.66 8.53 0.13 
CMPD26 8.17 7.89 0.28 
CMPD28 5.61 5.61 0.00 
CMPD29 5.92 5.70 0.22 























6.97 6.78 0.19 
5. 70 5.88 -0.18 
6. 79 6.95 -0.16 
8.05 8.01 0.04 
5.44 5.51 -0.07 
5.94 6.24 -0.30 
6.09 6.08 0.01 
6.70 6.96 -0.26 
6.16 5.86 0.30 
6.36 6.36 0.00 
8.29 8.24 0.05 
7.37 7.12 0.25 
7.16 7.25 -O.o9 
5.60 5.94 -0.34 
6.81 6.74 O.o7 
5.65 5.78 -0.13 
5.57 5.78 -0.21 
6.40 6.42 -0.02 
8.22 8.53 -0.30 
8.37 8.29 0.08 
7.33 7.56 -0.23 
5.80 5.62 0.18 
CMPD60 6.27 6.16 0.11 
Modified P A B t1 
CMPD61 ? 5.59 -2.66 
CMPD62 ? 8.25 0.00 
CMPD63 ? 5.03 -1.98 
CMPD64 ? 6.54 -0.98 
CMPD65 ? 8.22 -0.31 
CMPDI30 ? 9.09 0.80 






















































































































































Table 3b Set 3 CoMSIA All 
EA PA RES 
CMPD01 9.57 8.65 0.92 
CMPD13 7.18 7.02 0.16 
CMPD14 5.67 5.41 0.26 
CMPD16 6.04 5.70 0.34 
CMPD17 5.16 5.26 -0.10 
CMPD18 6.34 6.62 -0.28 
CMPD19 8.34 8.39 -0.05 
CMPD20 6.71 6.74 -0.03 
CMPD21 7.62 7.77 -0.15 
CMPD22 7.72 8.01 -0.29 
CMPD24 8.45 8.71 -0.25 
CMPD25 8.66 8.70 -0.04 
CMPD26 8.17 7.34 0.83 
CMPD28 5.61 6.16 -0.55 
CMPD29 5.92 5.69 0.23 
CMPD31 6.97 7.43 -0.46 
CMPD33 5.70 5.37 0.33 
CMPD34 6.79 7.42 -0.62 
CMPD35 8.05 7.65 0.40 
CMPD38 5.44 5.16 0.28 
CMPD39 5.94 6.56 -0.62 
CMPD40 6.09 6.34 -0.25 
CMPD42 6.16 5.94 0.22 
CMPD43 6.36 6.56 -0.20 
CMPD45 8.29 8.40 -0.11 
CMPD46 7.37 6.89 0.48 
CMPD47 7.16 6.61 0.55 
CMPD48 5.60 5.76 -0.16 
CMPD49 6.81 6.44 0.37 
CMPD50 5.65 6.34 -0.69 
CMPD51 5.57 5.93 -0.36 
CMPD53 6.40 6.42 -0.02 
CMPD54 8.22 8.31 -0.09 
CMPD55 8.37 8.15 0.22 
CMPD56 7.33 7.45 -0.12 
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Table 3c Set 3 CoMF A Cmpds 10-38 
EA PAB RESB PAE RESE PAS RESS 
CMPD11 7.38 7.42 -0.04 7.52 -0.13 7.31 0.07 
CMPD12 7.40 7.35 0.05 7.36 0.04 7.48 -0.08 
CMPD13 7.18 7.11 0.07 7.21 -0.03 7.07 0.12 
CMPD14 5.67 5.66 0.01 5.64 0.03 5.73 -0.06 
CMPD15 5.84 5.83 O.ot 5.81 0.03 5.91 -0.07 
CMPD16 6.04 6.06 -0.02 5.98 0.06 6.03 O.ol 
CMPD17 5.16 5.13 0.03 5.16 0.00 5.14 0.02 
CMPD18 6.34 6.32 0.02 6.36 -0.02 6.37 -0.03 
CMPD19 8.34 8.26 0.08 8.36 -0.02 8.45 -0.11 
CMPD20 6.71 6.68 0.03 6.69 0.02 6.71 0.00 
CMPD21 7.62 7.68 -0.06 7.67 -0.05 7.72 -0.09 
CMPD22 7.72 7.75 -0.03 7.59 0.13 7.87 -0.15 
CMPD25 8.66 8.70 -0.04 8.60 0.06 8.36 0.30 
CMPD26 8.17 8.07 0.10 8.19 -0.02 8.31 -0.14 
CMPD28 5.61 5.79 -0.18 5.47 0.14 5.63 -0.02 
CMPD29 5.92 5.92 0.00 5.93 -0.01 5.91 O.ot 
CMPD32 7.28 7.32 -0.04 7.30 -0.02 7.24 0.04 
CMPD33 5.70 5.68 0.02 5.66 0.04 5.69 O.Ql 
CMPD34 6.79 6.82 -0.03 6.98 -0.19 6.71 0.08 
CMPD35 8.05 8.10 -0.05 7.93 0.12 7.98 0.07 
CMPD38 5.44 5.37 0.07 5.62 -0.18 5.40 0.04 
Modified PAB 1:!. PAE !J.. PAS 1:!. 
CMPD145 ? 8.33 -0.37 8.08 -0.53 7.96 -0.40 
CMPD146 ? 7.73 -0.98 7.36 -1.25 7.53 -0.83 
CMPD147 ? 8.72 0.02 8.58 -0.02 8.35 -0.01 
CMPD148 ? 7.89 -0.37 8.22 -0. 13 8.39 -0.06 
CMPD149 ? 8.28 0.02 8.29 -0.07 8.43 -0.01 
Table 3d Set 3 CoMFA C~ds 10-47 
EA PAB RESB PAE RESE PAS RESS 
CMPD11 7.38 7.57 -0.19 7.38 0.00 7.50 -0.12 
CMPD12 7.40 7.42 -0.02 7.41 -0.01 7.61 -0.21 
CMPD13 7.18 7.13 0.05 6.94 0.24 7.03 0.15 
CMPD14 5.67 5.52 0.15 5.73 -0.06 5.62 0.05 
CMPD15 5.84 5.79 0.06 5.73 0.11 5.90 -0.06 
CMPD16 6.04 6.07 -0.03 6.14 -0.10 5.95 0.09 
CMPD17 5.16 5.21 -0.05 5.19 -0.03 5.31 -0. 15 
CMPD18 6.34 6.30 0.04 6.36 -0.02 6.04 0.30 
CMPD19 8.34 8.21 0.13 8.34 0.00 8.34 0.00 
CMPD20 6.71 6.78 -0.07 6.83 -0.12 6.87 -0.16 
CMPD2 1 7.62 7.65 -0.03 7.56 0.06 7.77 -0.15 
CMPD22 7.72 7.82 -0.10 7.52 0.20 8.07 -0.35 
CMPD25 8.66 8.65 0.01 8.58 0.08 7.98 0.68 
CMPD26 8.17 7.97 0.20 8.01 0.16 8.05 0.12 
CMPD28 5.61 5.83 -0.22 5.65 -0.04 5.54 0.07 
CMPD29 5.92 5.83 0.09 5.79 0.14 5.99 -0.07 
CMPD32 7.28 7.46 -0.18 . 7.208 0.07 7.59 -0.31 
CMPD33 5.70 5.62 0.08 5.67 0.03 5.55 0.15 
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Table 3d Set 3 CoMF A Cmpds 10-4 7 cont. 
CMPD34 6.79 6.82 -0.03 7.39 -0.60 6.56 0.23 
CMPD35 8.05 8.12 -0.07 8.26 -0.21 7.99 0.06 
CMPD38 5.44 5.48 -0.03 5.57 -0.13 5.26 0.18 
CMPD39 5.94 6.18 -0.24 6.26 -0.32 6.20 -0.26 
CMPD40 6.09 6.08 0.01 5.94 0.15 6.14 -0.05 
CMPD41 6.70 6.69 0.01 6.74 -0.04 6.87 -0.17 
CMPD42 6.16 6.12 0.04 6.27 -0.11 6.51 -0.35 
CMPD43 6.36 6.26 0.10 6.25 0.11 6.71 -0.35 
CMPD45 8.29 8.27 0.02 8.38 -0.09 8.01 0.28 
CMPD46 7.37 7.30 0.07 6.90 0.48 7.36 0.01 
CMPD47 7.16 6.97 0.19 7.11 0.05 6.79 0.37 
Modified PAB !:i PAE !:i PAS !:i 
CMPD147 ? 8.71 0.05 8.57 -0.01 8.04 0.06 
CMPD149 ? 8.26 0.05 8.23 -0.12 8.42 0.08 
CMPD150 ? 8.75 0.10 8.51 -0.07 8.13 0.16 
CMPD151 ? 7.72 -0.93 8.00 -0.58 8.00 0.02 
CMPD152 ? 7.67 -0.98 6.91 -1.67 7.59 -0.39 
CMPD153 ? 8.26 0.05 7.93 -0.41 8.44 0.11 
Table 3e Set 3 CoMFA CmEds48-60 
EA PAB RESB PAE RESE PAS RESS 
CMPD01 9.57 9.66 -0.09 9.54 0.03 9.57 0 
CMPD48 5.60 6.01 -0.41 5.64 -0.04 5.60 0 
CMPD49 6.81 6.43 0.38 6.69 0.12 6.81 0 
CMPD50 5.65 5.88 -0.23 5.63 0.02 5.65 0 
CMPD51 5.57 5.58 -0.01 5.70 -0.13 5.57 0 
CMPD53 6.40 6.43 -0.03 6.38 0.02 6.40 0 
CMPD54 8.22 8.25 -0.03 8.29 -0.07 8.22 0 
CMPD56 7.33 7.16 0.17 7.35 -0.01 7.33 0 
CMPD57 5.80 5.81 -0.01 5.68 0.12 5.80 0 
CMPD60 6.27 6.01 0.26 6.32 -0.05 6.27 0 
Modified PAB !:i PAE !:i PAS !:i 
CMPD154 ? 8.45 0.20 7.73 -0.56 8.52 0.30 
CMPD155 ? 8.49 0.24 8.18 -0.1 1 8.46 0.24 
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(E)-9a, (Z)-9a lOa-d 
Table 4 Set 4 Com,eounds 
Compound R• R2 R3 R4 n m bio. act. 
compOl 1.08 
cmpd08a CHP H H CF3 3 -0.22 
cmpd08b CH30 H H CF3 2 1.33 
cmpd08c CH30 H H CH3 0.88 
cmpd08d CHP H H C2Hs 1.14 
cmpd08e CH30 H H (CH02CH3 1.26 
cmpd08f CH30 H H (CH2) 3CH3 -0.12 
cmpd08g CH30 H H CH(CH3)2 0.60 
cmpd08h CH30 H H CF3 1.65 
cmpd08i CH30 7-CH3 H CF3 -1.45 
cmpd08j CH30 5-CH3 H CF3 1.01 
cmpd08k CH30 7-CH30 H CF3 -1.67 
cmpd081 CH30 5-CHP H CFJ -0.61 
cmpd08m CH30 H C6H5 CF3 -0.20 
cmpd08n H H H CF3 -1 .09 
cmpd09a(E) C2Hs 0.68 
cmpd09a(Z) C2Hs 0.03 
cmpdlOa H C2Hs 1.64 
cmpdlOb H CF3 1.39 
cmpdlOc C6Hs CF3 2.22 
cmpdlOd CH2C6H5 CFJ -0.84 
cmpd13 CH30 H H CFJ 0 -1.46 
cmpd19 CHP H H CF3 2 0.28 
cmpd20 OH H H C2Hs -1.38 
cmpd21a ~H50 H H C2Hs 1.00 
cmpd21b CH3{CH2)20 H H CzHs 0.37 
cmpd21c (CH3)2CHO H H C2Hs -0.16 
Test Original Modification{ s} 
cmpd22 cmpdlOc OCH2CH3 
cmpd23 cmpdiOc delete =0 
cmpd24 cmpdlOa OCH2CH3 
cmpd25 cmpd08h OCH2CH3 
cmpd26 cmpdlOc OCH2CH(CH3)2 
cmpd27 cmpdlOc OCH2CHzCH3 
cmpd28 cmpdlOc CH2CH2CH3 
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Table 4 Set 4 Compounds cont. 
Test Original Modification( s) 
cmpd29 cmpdlOc CH2C(CH3)3 
cmpd30 cmpdlOc OC(CH3)3 
cmpd31 cmpdlOc 0-Ph 
cmpd32 cmpdlOc delete F 
cmpd33 cmpdlOc delete Ph group 
cmpd34 cmpdlOc OCH(CH3)2 
cmpd35 cmpdlOc OCH2CH3 
cmpd36 cmpdlOa replace N with 0 
cmpd37 cmpdJOc C16(CH3)3 
cmpd38 cmpd08h C1~(CF3h 
cmpd39 cmpdJOa replace C16 with 0 
cmpd40 cmpdJOa OCH2CH3 
cmpd41 cmpdlOa OCH(CH3h 
cmpd42 cmpdlOa 16 ) OCH2CH3, C (CH3 3 
cmpd43 cmpdlOa CBr 
cmpd44 cmpdlOa OCH2CH3, C16(CH3)3, C Br 
cmpd45 cmpdlOb CBr 
cmpd46 cmpdlOb OCH2CH3, CBr 
cmpd47 cmpdlOb c••(CH3)2-
cmpd48 cmpdlOb N-CH3 
cmpd49 cmpdlOb OCH2CH3 
cmpdSO cmpdlOb CH2CF3 
cmpd51 cmpdlOb N-C(CH3)3 
cmpd52 cmpdlOa N-CH(CH3h 
crnpd53 cmpdlOa {)(:H2CH3, N-CH(CH3)2 
cmpd54 cmpdlOb N-CH(CH3)2 
cmpd55 cmpdlOb {)(:H2CH3, N-CH(CH3h 
crnpd56 cmpdOI N-CH3 
cmpd57 cmpdlOb replace F with H 
cmpd58 cmpdlOb replace =0 with Br and CH3 
cmpd59 cmpdOI C13(CH3h-
cmpd60 cmpdOl C 13HBr-




Set 4: Summary of the Statistical Results for the PLS Analyses s.a 
HumanMT1 Hamster MT3 
CoMFAb CoMFA0 CoMSJAd 
B E s B E s 
Q2 0.541 0.346 0.611 0.706 0.794 0.696 0.642 
no. comp 6 4 6 6 5 6 3 
s 0.116 0.186 0.144 0.065 O.o78 0.051 0.187 
R2 0.993 0.979 0.989 0.995 0.991 0.997 0.947 
F 363.027 209.191 236.837 362.749 300.282 576.504 95.831 
Prob. R2=0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
• Alignment using cmpd08c as the basic molecule b Outliers: 8d, Sf, 2 1a, 21c <Outliers: 8b, 8j, 9ae, 9az, I Od, 2lc 4 Outliers: 8c, 8h, 8k, 9az, 
IOd 
Table 4a Set 4 CoMFA HumanMT1 
EA PAB RESB PAE RESE PAS RESS 
CMPD01 1.08 1.10 -0.02 1.27 -0.19 1.02 0.06 
CMPD08A -0.22 -0.31 0.09 -0.27 0.05 -0.31 0.09 
CMPD08B 1.33 1.34 -0.01 1.32 0.01 1.40 -0.07 
CMPD08C 0.88 0.76 0.12 0.81 0.07 0.76 0.12 
CMPD08E 1.26 1.22 0.04 1.42 -0.16 1.25 0.01 
CMPD08G 0.60 0.64 -0.04 0.48 0.12 0.70 -0.10 
CMPD08H 1.65 1.32 0.33 1.41 0.24 1.30 0.35 
CMPD081 -1.45 -1.55 0.10 -1.01 -0.44 -1.51 0.06 
CMPD08J 1.01 1.15 -0.14 1.20 -0.19 1.16 -0.15 
CMPD08K -1.67 -1.71 0.04 -1.63 -0.04 -1.61 -0.06 
CMPD08L -0.61 -0.58 -0.03 -0.61 0.00 -0.63 0.02 
CMPD08M -0.20 -0.10 -0.10 -0.15 -0.05 -0.08 -0.12 
CMPD08N -1.09 -1.12 0.03 - 1.29 0.20 -1.03 -0.06 
CMPD09AE 0.68 0.79 -0.11 0.89 -0.21 0.87 -0.19 
CMPD09AZ 0.03 0.12 -0.09 -0.02 0.05 0.17 -0.14 
CMPD 10A 1.64 1.61 0.03 1.48 0.16 1.52 0.12 
CMPD10B 1.39 1.44 -0.04 1.50 -0.10 1.48 -0.09 
CMPD10C 2.22 2.25 -0.03 2.17 0.06 2.15 0.07 
CMPD10D -0.84 -0.85 0.01 -0.97 0.13 -0.86 0.02 
CMPD13 -1.46 -1.42 -0.04 -1.57 0.11 -1.53 0.07 
CMPD19 0.28 0.25 0.03 0.12 0.16 0.27 0.01 
CMPD20 -1.38 -1.33 -0.05 -1.20 -0.18 -1.49 0.11 
CMPD21B 0.37 0.48 -0.11 0.18 0.19 0.50 -0.13 
Modified EA PAB !:J. PAE !:J. PAS !:J. 
CMPD22 ? 2.28 0.03 0.95 -1.22 2.39 0.24 
CMPD23 ? 1.53 -0.72 2.23 0.07 2.16 O.Ql 
CMPD24 ? 1.70 0.08 0.42 -1.06 1.75 0.23 
CMPD25 ? 1.39 0.07 0.34 -1.07 1.54 0.24 
CMPD26 ? 2.13 -0.12 0.75 -1.42 2.44 0.29 
CMPD27 ? 2.26 0.01 0.88 -1.29 2.37 0.22 
CMPD28 ? 1.74 -0.51 -0.61 -2.78 2.36 0.21 
CMPD29 ? 1.43 -0.82 -0.56 -2.72 1.78 -0.37 
61 
Table 4a Set 4 CoMF A Human MT1 cont. 
Modified EA PAB l1 PAE l1 PAS l1 
CMPD30 ? 1.81 -0.44 1.41 -0.75 1.77 -0.38 
C:MPD31 ? 1.52 -0.73 0.67 -1.50 2.00 -0.15 
CMPD32 ? 2.53 0.28 2.09 -0.08 2.16 O.ot 
CMPD33 ? 1.40 -0.85 1.21 -0.96 1.59 -0.56 
CMPD34 ? 2.17 -0.08 1.28 -0.88 2.39 0.24 
CMPD35 ? 1.76 -0.49 0.62 -1.55 2.36 0.21 
CMPD36 ? 1.80 0.19 1.87 0.39 1.95 0.43 
CMPD37 ? 1.83 -0.42 1.50 -0.66 1.68 -0.47 
CMPD38 ? 1.23 -0.09 1.45 0.05 1.46 0.16 
Table 4b Set 4 CoMFA HumanMT3 
EA PAB RESB PAE RESE PAS RESS 
CMPD01 -1.44 -1.47 0.03 -1.43 -0.01 -1.45 0.01 
CMPD08C -2.50 -2.56 0.05 -2.70 0.20 -2.51 0.01 
CMPD08D -2.84 -2.92 0.08 -2.74 -0.10 -2.97 0.13 
CMPD08E -2.98 -2.91 -0.07 -3.04 0.06 -2.90 -0.08 
CMPD08F -2.92 -2.98 0.06 -2.91 -0.01 -2.95 0.03 
CMPD08G -3.36 -3.33 -0.03 -3.29 -0.07 -3.36 0.00 
CMPD08H -2.70 -2.60 -0.10 -2.66 -0.04 -2.64 -0.06 
CMPD081 -3.41 -3.46 0.05 -3.48 0.07 -3.42 O.ot 
CMPD08K -3.50 -3.52 0.02 -3.45 -0.05 -3.50 0.00 
CMPD08L -2.89 -2.93 0.04 -2.82 -0.07 -2.89 0.00 
CMPD08M -3.25 -3.24 -0.01 -3.27 O.Ql -3.27 0.02 
CMPD10A -1.69 -1.71 0.02 -1.65 -0.04 -1.69 0.00 
CMPD10B -0.96 -0.96 0.00 -0.97 O.ot -0.99 0.03 
CMPD10C -1.68 -1.64 -0.04 -1.72 0.04 -1.66 -0.02 
CMPD13 -2.63 -2.60 -0.03 -2.63 0.00 -2.62 -0.01 
CMPD19 -2.55 -2.59 0.04 -2.53 -0.02 -2.55 0.00 
CMPD20 -3.26 -3.19 -0.07 -3.24 -0.02 -3.22 -0.04 
CMPD21A -2.88 -2.92 0.04 -2.92 0.04 -2.89 0.01 
CMPD218 -2.91 -2.83 -0.08 -2.91 0.00 -2.89 -0.03 
Modified EA PAB l1 PAE l1 PAS l1 
CMPD24 ? -1.53 0.19 -1.76 -0.11 -1.52 0.17 
CMPD47 ? -1.25 -0.29 -1.15 -0.18 1.40 2.39 
CMPD48 ? -0.90 0.06 -1.01 -0.04 -0.93 0.05 
CMPD49 ? -0.81 0.15 -0.99 -0.02 -0.83 0.16 
CMPD50 ? -1.26 -0.30 -1 .27 -0.30 -1.37 -0.38 
CMPD51 ? -0.97 -0.01 -0.91 0.06 -0.96 0.02 
CMPD52 ? -1.55 0.16 -1.25 0.40 -1.58 0.11 
CMPD53 ? -1.38 0.33 -1.34 0.31 -1.39 0.30 
CMPD54 ? -0.93 0.03 -0.95 0.02 -0.94 0.05 
CMPD55 ? -0.80 0.16 -0.99 -0.02 -0.83 0.15 
CMPD56 ? -1.40 0.31 -1.34 0.31 -1.42 0.27 
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Table 4c Set 4 CoMSIA MT3 
EA PA RES 
CMPD01 -1 .44 -1.54 0.10 
CMPD08B -2.78 -3.05 0.27 
CMPD08D -2.84 -3.05 0.21 
CMPD08E -2.98 -3.01 0.03 
CMPD08F -2.92 -3.00 0.08 
CMPD08G -3.36 -3.32 -0.04 
CMPD081 -3.41 -3.21 -0.20 
CMPD08J -3.66 -3.32 -0.34 
CMPD08L -2.89 -2.99 0.10 
CMPD08M -3.25 -3.40 0.15 
CMPD09AE -3.08 -2.93 -0.15 
CMPD10A -1.69 -1.5 1 -0. 18 
CMPD10B -0.96 -1.05 0.09 
CMPD10C -1.68 -1.60 -0.08 
CMPD13 -2.63 -2.51 -0.12 
CMPD19 -2.55 -2.50 -0.05 
CMPD20 -3.26 -3.20 -0.06 
CMPD21A -2.88 -3.10 0.22 
CMPD21B -2.91 -3.06 0.15 
CMPD21C -3.74 -3.57 -0.17 
Modified EA PA !1 
CMPD45 ? -1.01 0.04 
CMPD46 ? -1.02 0.03 
CMPD48 ? -1.63 -0.58 
CMPD49 ? -1.09 -0.04 
CMPD54 ? -1.75 -0.70 
CMPD55 ? - 1.75 -0.70 
CMPD57 ? -1.06 -0.01 
CMPD58 ? -1.58 -0.53 
CMPD59 ? -1.61 -0.07 
CMPD60 ? -1.71 -0.17 
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72-94 95-104 105 
Table 5 Set 5 COQ!EOunds 
Compound RI R2 norx RJ ~ bio. act. 
cmpd01 OCH3 H NH CH3 9.57 
cmpd72 7-0CH3 H H CH3 10.12 
cmpd73 7-0CH3 H H n-C3H7 11.46 
cmpd74 7-0CH3 H H CsH9 6.51 
cmpd75 7-0CH3 H H C6HII 6.36 
cmpd76 7-0CH3 H H CH2Br 11.93 
cmpd77 7-0CH3 H H n-C3H6Cl 10.82 
cmpd78 7-0CH3 H H C6Hs 5.60 
cmpd79 7-0CH3 H H (3,5-diCIC6H3) 5.00 
cmpd80 7-0CH3 H H (2-indolyl) 5.57 
cmpd81 7-0CH3 H H CH2C6Hs 5.01 
cmpd82 7-0CH3 H H CH(C6H5) 2 4.99 
cmpd83 7-0CH3 H H (CH2hC6Hs 5.58 
3 2 2 6 5 
cmpd85 7-0CH) H H CHr4-morph 6.50 
cmpd86 7-0CH3 H H CH2-TMZ 5.52 
cmpd87 7-0CH3 H 1 NR3R4 = 2-pyrr 7.00 
cmpd88 7-0CH) H 1 CH3 CH3 7.59 
cmpd89 7-0CH) H CH3 C4H7 5.88 
cmpd90 6-0CH3 H H CH3 6.91 
cmpd91 6-0CH) H H C4H7 5.73 
cmpd92 6-0CH3 H H CF3 5.73 
cmpd93 7-0CH3 H I H CH3 6.61 
cmpd94 7-0CH) COOCH3 I H CH3 7.50 
cmpd95 OCH3 H NH H C3Hs 13.30 
cmpd96 OCH3 H NH H CH21 9.01 
cmpd97 OCH3 H NH F C3Hs 8.72 
cmpd98 OCH3 H 0 H CH3 8.77 
cmpd99 OCH3 H 0 H n-C4H9 8.24 
cmpdlOO OCH3 H 0 H C3Hs 8.26 
cmpd101 OCH3 H s H CHJ 8.92 
cmpd102 OCH3 H s H C3Hs 8.40 
cmpd103 OCH3 H s H C4H7 7.33 
cmpd104 OCH3 H s H CH2I 8.41 
cmEd105 OCH3 H H CH3 5.28 
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Table 5 Set 5 Compounds cont. 
Test Orig!nal Modification{ s 2 
cmpdl06 cmpd81 OCH2CH3 
cmpdl07 cmpd81 c•6p 
cmpd108 cmpd81 C17F 
cmpd109 cmpd81 C16p C11F 
' 
cmpdllO cmpd81 c43(CHJh-
cmpdlll cmpd81 c26CH3 
cmpdll2 cmpd94 ~·cH3 
cmpdll3 cmpd94 OCH2CH3 
cmpdl14 cmpd94 c•4F 
cmpd115 cmpd96 C14(CH3h-
cmpd116 cmpd96 N-NH2 
cmpd117 cmpd96 c•4I3 
cmpdl18 cmpd96 replace =0 with F 
cmpdl19 cmpd96 remove I 
cmpd120 cmpd96 replace I with CH3 I 
cmpd121 cmpd97 OCH2CH3 
cmpd122 cmpd97 C26CH3 
cmpd123 cmpd97 C 14CH3 
cmpd124 cmpd97 c••p 
cmpd125 cmpd99 OCH2CH3 
cmpd126 cmpd99 C 14CH3 
cmpdl27 cmpd99 ~6CH3 
cmpd128 cmpd99 ~8CH3 
cmpd129 cmpd99 CllF2 
a ML T b morph: morpholino c TMZ: 1-(2',3',4'-trimethoxybenzyl) d 2-pyrr: 2-pyrrolidinone 
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Table SA 
Set 5: Summary of the Statistical Results for the PLS Analyses 18·" 
Ovine Pars Tuberalis Membrane Binding 
All Cmpds 72-94 
CoMFAb CoMSIA' CoMFAd CoMStA• 
B E s B E s 
Q2 0.835 0.843 0.823 0.84 1 0.780 0.418 0.592 0.583 
no. comp 5 5 5 2 6 4 5 6 
s 0.173 0.229 0.219 0.358 0.070 0.352 0.163 0.108 
R2 0.986 0.976 0.978 0.934 0.995 0.850 0.970 0.986 
F 320.871 181.258 197.153 176.599 396.785 19.864 84.248 116.376 
Prob. R2=0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cmpds 95-105 
CoMFAr CoMSIA1 
B E s 
Q2 0.357 0.615 0.411 0.798 
no. comp 5 3 4 3 
s 0.003 0.123 0.042 0.032 
R2 1.000 0.977 0.998 0.992 
F 34293.898 42.791 280.345 124.651 
Prob. R2=0 0.004 0.006 0.004 0.001 
• Alignment using cmpdl s<2') as the basic molecule b Outliers: 72, 73, 76, 77, 76, 105 'Outliers: 72, 73, 76, 77, 95, 105 d Outliers: 72, 73, 76, 
77 'Outliers: 72, 73, 76, 77, 87,94 r Outlien;: 102, 105 8 Outliers: 95, 96, 103, 105 
Table Sa Set 5 CoMFA All 
EA PAB RESB PAE RESE PAS RESS 
CMPD74 6.51 6.30 0.22 6.55 -0.04 6.41 0.10 
CMPD75 6.36 6.45 -0.09 6.34 0.02 6.58 -0.22 
CMPD78 5.60 5.63 -0.03 5.49 0.11 5.70 -0.10 
CMPD79 5.00 5.04 -0.04 4.98 0.02 4.90 0.10 
CMPD80 5.57 5.73 -0.16 5.54 0.04 5.67 -0.10 
CMPD8 1 5.01 5.06 -0.05 5.18 -0.17 5.18 -0.17 
CMPD82 4.99 4.95 0.04 5. 17 -0. 18 4.80 0.19 
CMPD83 5.58 5.57 0.01 5.62 -0.04 5.57 0.01 
CMPD84 5.61 5.40 0.21 5.55 0.06 5.44 0.17 
CMPD85 6.50 6.51 -0.01 6.64 -0.13 6.46 0.04 
CMPD86 5.52 5.56 -0.04 5 .43 0.09 5.57 -0.05 
CMPD87 7.00 6.88 0.12 7.29 -0.29 6.85 0.15 
CMPD88 7.59 7.50 0.09 7.02 0.57 7.60 0.00 
CMPD89 5.88 6.06 -0.18 5.77 0.11 6.27 -0.39 
CMPD90 6.91 6.92 -0.01 6.98 -0.07 6.64 0.27 
CMPD91 5.73 5.75 -0.02 5.80 -0.07 5.49 0.24 
CMPD92 5.73 5.67 0.06 5.53 0.20 5.99 -0.26 
CMPD93 6.61 6.60 O.Ql 6.76 -0.1 5 6.57 0.04 
CMPD94 7.50 7.48 0.02 7.67 -0.17 7.62 -0.12 
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Table Sa Set 5 CoMFA All cont. 
EA PAB RESB PAE RESE PAS RESS 
CMPD96 9.01 8.67 0.34 8.89 0.12 8.70 0.31 
CMPD97 8.72 8.78 -0.06 8.72 0.00 8.71 O.ol 
CMPD98 8.77 9.03 -0.26 8.64 0.13 9.03 -0.26 
CMPD99 8.24 8.27 -0.03 8.39 -0.15 8.10 0.14 
CMPD100 8.26 8.34 -0.08 8.09 0.17 8.19 0.07 
CMPD101 8.92 8.74 0.18 8.76 0.16 8.77 0.15 
CMPD102 8.40 8.15 0.25 8.01 0.39 8.15 0.25 
CMPD103 7.33 7.73 -0.40 7.72 -0.39 7.77 -0.44 
CMPD104 8.41 8.52 -0.11 8.74 -0.33 8.54 -0.13 
Modified PAB 6. PAE fl. PAS 6. 
CMPD106 ? 5.69 0.63 5.75 0.57 5.78 0.60 
CMPD107 ? 5.40 0.34 5.33 0.15 5.16 -0.01 
CMPD108 ? 5.43 0.37 5.55 0.37 5.10 -0.07 
CMPD109 ? 5.78 0.72 5.82 0.64 5.09 -0.08 
CMPDllO ? 4.78 -0.28 4.70 -0.48 4.79 -0.39 
CMPD111 ? 4.76 -0.30 4.91 -0.27 4.97 -0.21 
CMPD112 ? 6.65 -0.83 7.39 -0.28 6.61 -1.01 
CMPD113 ? 7.29 -0.18 7.40 -0.28 7.45 -0.17 
CMPD114 ? 7.52 0.04 7.70 0.03 7.62 0.00 
CMPD115 ? 7.87 -0.79 8.77 -0.12 7.78 -0.93 
CMPD116 ? 8.30 -0.37 9.15 0.25 8.20 -0.51 
CMPD117 ? 7.07 -1.59 8.23 -0.66 6.77 -1.93 
CMPD1 18 ? 7.96 -0.71 8.11 -0.78 8.33 -0.37 
CMPD1 19 ? 8.87 0.20 8.83 -0.07 8.98 0.28 
CMPD120 ? 8.87 0.20 8.77 -0.12 8.89 0.19 
CMPD121 ? 8.82 0.04 8.65 -0.07 8.79 0.08 
CMPD 122 ? 8.41 -0.37 8.94 0.23 8.37 -0.33 
CMPD123 ? 8.46 -0.33 8.73 O.ol 8.40 -0.31 
CMPD124 ? 9.05 0.26 9.10 0.39 8.69 -0.02 
CMPD125 ? 8.33 0.06 8.32 -0.07 8.20 0.09 
CMPD126 ? 7.94 -0.33 8.31 -0.08 7.78 -0.32 
CMPD127 ? 8.58 0.31 8.38 -0.01 8.50 0.40 
Table Sb Set 5 CoMSIA All 
EA PA RES 
CMPD74 6.51 5.93 0.58 
CMPD75 6.36 5.82 0.55 
CMPD78 5.60 5.72 -0.12 
CMPD79 5.00 5.22 -0.22 
CMPD80 5.57 5.52 0.05 
CMPD81 5.01 5.38 -0.37 
CMPD82 4.99 4.71 0.29 
CMPD83 5.58 5.58 0.00 
CMPD84 5.61 5.54 0.07 
CMPD85 6.50 6.75 -0.25 
CMPD86 5.52 5.81 -0.29 
CMPD87 7.00 7.15 -0.15 
CMPD88 7.59 6.99 0.60 
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Table Sb Set 5 CoMSIA All 
EA PA RES 
CMPD89 5.88 6.13 -0.25 
CMPD90 6.91 6.78 0.13 
CMPD91 5.73 5.93 -0.20 
CMPD92 5.73 5.92 -0.19 
CMPD93 6.61 7.00 -0.39 
CMPD94 7.50 7.52 -0.02 
CMPD96 9.01 8.97 0.04 
CMPD97 8.72 8.67 0.05 
CMPD98 8.77 8.66 0.11 
CMPD99 8.24 7.65 0.59 
CMPD100 8.26 8.35 -0.09 
CMPD101 8.92 8.33 0.59 
CMPD102 8.40 8.47 -0.07 
CMPD103 7.33 8.15 -0.82 
CMPD104 8.41 8.63 -0.22 
Modified PA A 
CMPD106 ? 5.57 0.19 
CMPD107 ? 5.45 0.07 
CMPD108 ? 5.45 0.07 
CMPD109 ? 5.54 0.17 
CMPD110 ? 5.12 -0.26 
CMPD111 ? 5.09 -0.29 
CMPDI12 ? 7.08 -0.44 
CMPD113 ? 7.51 -0.01 
CMPD114 ? 7.46 -0.06 
CMPD115 ? 8.84 -0.13 
CMPD116 ? 8.33 -0.64 
CMPD117 ? 9.10 0.13 
CMPD118 ? 8.24 -0.73 
CMPD119 ? 9.14 0.18 
CMPD120 ? 8.85 -0.12 
CMPD121 ? 9.33 0.66 
CMPD122 ? 8.80 0.13 
CMPD123 ? 9.14 0.47 
CMPD124 ? 9.31 0.64 
CMPD125 ? 7.68 0.03 
Table Sc Set 5 CoMFA 72-94 
EA PAB RESB PAE RESE PAS RESS 
CMPD74 6.51 6.50 O.ot 6.75 -0.24 6.53 -0.02 
CMPD75 6.36 6.40 -0.04 6.60 -0.24 6.25 0.11 
CMPD78 5.60 5.60 0.00 5.45 0.15 5.65 -0.05 
CMPD79 5.00 5.02 -0.02 4.97 0.03 5.01 -0.01 
CMPD80 5.57 5.56 O.ot 5.62 -0.05 5.51 0.06 
CMPD81 5.01 4.93 0.08 4.90 0.11 5.01 0.00 
CMPD82 4.99 4.97 0.02 5.03 -0.04 5.12 -0.13 
CMPD83 5.58 5.63 -0.05 5.57 O.ot 5.52 0.06 
CMPD84 5.61 5.62 -0.01 5.75 -0.14 5.60 0.01 
CMPD85 6.50 6.45 0.05 6.35 0.15 6.61 -0.11 
CMPD86 5.52 5.59 -0.07 5.80 -0.28 5.46 0.06 
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Table Sc Set 5 CoMF A 72-94 cont. 
EA PAB RESB PAE RESE PAS RESS 
CMPD87 7.00 7.02 -0.02 6.84 0.16 6.97 0.04 
CMPD88 7.59 7.45 0.14 6.65 0.94 7.45 0.14 
CMPD89 5.88 5.93 -0.05 6.08 -0.20 6.14 -0.26 
CMPD90 6.91 6.95 -0.04 6.53 0.38 6.75 0.16 
CMPD91 5.73 5.63 0.10 6.23 -0.50 5.43 0.30 
CMPD92 5.73 5.76 -0.03 5.83 -0.10 6.01 -0.28 
CMPD93 6.61 6.63 -0.02 6.47 0.14 6.60 0.01 
CMPD94 7.50 7.56 -0.06 7.80 -0.30 7.59 -0.09 
Modified PAB fl. PAE fl. PAS fl. 
CMPD106 ? 5.58 0.65 4.96 0.06 5.64 0.63 
CMPD107 ? 5.12 0.19 5.20 0.31 5.01 0.00 
CMPD108 ? 5.30 0.37 5.34 0.44 4.98 -0.03 
CMPD109 ? 5.52 0.59 5.78 0.88 4.98 -0.03 
CMPD110 ? 4.79 -0.14 5.38 0.48 4.81 -0.21 
CMPD111 ? 4.94 O.Ql 5.07 0.18 5.18 0.17 
CMPD112 ? 6.54 -1.02 7.83 0.03 6.26 -1.33 
CMPD113 ? 7.48 -0.08 7.85 0.05 7.42 -0.17 
CMPD114 ? 7.58 0.02 7.87 0.07 7.59 0.00 
Table 5d Set 5 CoMSIA 72-94 
EA PA RES 
CMPD74 6.51 6.32 0.19 
CMPD75 6.36 6.34 0.02 
CMPD78 5.60 5.69 -0.09 
CMPD79 5.00 4.95 0.05 
CMPD80 5.57 5.53 0.04 
CMPD81 5.01 4.90 0.11 
CMPD82 4.99 5.13 -0.14 
CMPD83 5.58 5.64 -0.06 
CMPD84 5.61 5.63 -0.02 
CMPD85 6.50 6.55 -0.05 
CMPD86 5.52 5.47 0.05 
CMPD88 7.59 7.50 0.09 
CMPD89 5.88 5.95 -0.07 
CMPD90 6.91 7.03 -0.12 
CMPD91 5.73 5.69 0.04 
CMPD92 5.73 5.76 -0.03 
CMPD93 6.61 6.63 -0.02 
Modified PA fl. 
CMPD106 ? 5.43 0.53 
CMPD107 ? 5.07 0.17 
CMPD108 ? 5.03 0.13 
CMPD109 ? 5.22 0.32 
CMPD110 ? 4.62 -0.28 
CMPD111 ? 4.70 -0.20 
CMPD112 ? 7.25 -0.25 
CMPD113 ? 8.07 0.57 
CMPD114 ? 8.10 0.60 
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Table 5e Set 5 CoMFA 95-105 
EA PAB RESB PAE RESE PAS RESS 
CMPD96 9.01 9.01 0.00 9.01 0.00 9.00 0.01 
CMPD97 8.72 8.72 0.00 8.64 0.08 8.69 0.03 
CMPD98 8.77 8.77 0.00 8.79 -0.01 8.79 -0.02 
CMPD99 8.24 8.24 0.00 8.27 -0.03 8.24 0.00 
CMPD101 8.92 8.92 0.00 8.82 0.10· 8.91 O.Ql 
CMPD103 7.33 7.33 0.00 7.30 0.03 7.32 0.01 
CMPD104 8.41 8.41 0.00 8.58 -0.16 8.46 -0.05 
Modified PAB ll. PAE ll. PAS ll. 
CMPD116 ? 8.91 -0.11 9.07 0.06 8.93 -0.07 
CMPD117 ? 8.47 -0.54 8.98 -0.03 8.40 -0.60 
Table Sf Set 5 CoMSIA 95-1 05 
EA PA RES 
CMPD97 8.72 8.73 -0.01 
CMPD98 8.77 8.73 0.04 
CMPD99 8.24 8.24 0.00 
CMPD100 8.26 8.29 -0.03 
CMPD101 8.92 8.94 -0.02 
CMPD102 8.40 8.39 0.01 




5a-5e, 7a-7d, 10a-10d, 13 20a-21d 
Table 6; Set 6 - Group 1 Compounds Table 6;; Set 6 - Group 2 Compounds 
Compound R• R MT1 MT2 Compound R• R MT1 MT~ 
cmpd01 0.18 0.48 cmpd01 0.18 0.48 
cmpd02 -2.78 -1.65 cmpd02 -2.78 -1.65 
cmpd05a H Me -2.29 -1.23 cmpd20a H Me -2.59 -1.56 
cmpd05b H Et -2.31 -1.24 cmpd20b H Et -2.17 -0.97 
cmpd05c H Pr -2.24 -1.08 cmpd20c H Pr -1.85 -0.57 
cmpd05d H c-C3H5 -2.89 -2.35 cmpd20d H c-C4H7 -3.31 -2.55 
cmpd05e H c-C4H7 -3.08 -3.05 cmpd21a OMe Me -0.86 0.29 
cmpd07a OMe Me -0.26 1.22 cmpd21b OMe Et -0.77 0.92 
cmpd07b OMe Et -0.64 0.77 cmpd21c OMe Pr -0.61 0.70 
cmpd07c OMe Pr -0.65 1.30 cmpd2ld OMe c-C4H7 -2.64 -2.51 
cmpd07d OMe c-C3H5 -1.67 0.02 Test Orig!nal Modificationi s 2 
cmpd10a OEt Me -1.26 0.68 cmpd41 cmpd2lc R: n-Bu (up) 
cmpdlOb OEt Et -1.16 0.59 cmpd42 cmpd21c R: n-Bu (down) 
cmpdlOc OEt Pr -0.95 0.80 cmpd43 cmpd21b R 1: OEt 
crnpd10d OEt c-C3H5 -2.37 -0.74 cmpd44 cmpd21b R 1:0Pr 
C!!.!£dl3 Cl Me -2.45 -1.53 cmpd45 cmpd2lb R 1: 0-iPr 
Test Original Modification{s} cmpd46 cmpd2lb R 1:0MeOH 
cmpd31 cmpd07c R 1: 0-iPr cmpd57 cmpd2lb R 1: 0-tBu 
cmpd32 cmpd07c R 1: 0-tBu cmpd48 crnpd21c R: n-Bu (up), 
cmpd33 cmpd07c R:OH R 1:0MeOH 
• MLT b Luzindole 
crnpd34 cmpd07c R:F 
crnpd35 cmpd07c R1: 0-tBu, R : OH 
cmpd36 cmpd07c R1: 0-tBu, R : F 
cmpd37 cmpd07c OCH2CH3 
cmpd38 cmpd07c C44H2CH3 
c~d39 cmEd07c C44CH2CH3 





Table 6;;; Set 6 - Group 3 Compounds 
Compound Rl R MTI MT2 
cmpd01" 0.18 0.48 
cmpd02b 
-2.78 -1.65 
cmpd23a H Me -2.38 -2.35 
cmpd23b H Et -2.06 -1.66 
cmpd23c H Pr -1.90 -1.80 
cmpd23d H c-~H5 -2.07 -1.72 
cmpd23e H c-C4H7 -2.40 -2.49 
cmpd25a OMe Me -2.44 -0.80 
cmpd25b OMe Et -1.72 -0.15 
cmpd25c OMe Pr -1.82 0.30 
cmpd25d OMe c-~H5 -2.70 -1.08 
cmpd25e OMe c-C4H7 -2.88 -1.50 
cmpd27a OEt Me -2.71 -2.07 
cmpd27b OEt Et -2.43 -1.34 
cmpd27c OEt Pr -2.41 -0.81 
cmpd27d OEt c-C3H5 -3.47 -1.93 
cmEd30 Cl Me -2.46 -0.70 
a MLT b Luzindole 
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Table 6A 
Set 6: Summary of the Statistical Results for the PLS Analyses IO,a 
Human MT1 All Human MT 1 Table 6; 
CoMFAb CoMSIAc CoMFA CoMSIAd 
B E s B E s 
Q2 0.724 0.781 0.735 0.764 0.719 0.698 0.693 0.708 
no. comp 6 6 6 6 6 3 4 5 
s 0.208 0.235 0.215 0.283 0.165 0.302 0.213 0.166 
R2 0.959 0.947 0.956 0.920 0.984 0.929 0.968 0.984 
F 104.292 80.293 97.267 55.388 93.225 52.215 82.019 107.820 
Prob. R2=0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Human MT1 Table 6;; Human MT2 All 
CoMFA0 CoMSIAr CoMFAg CoMSIAb 
B E s B E s 
Q2 0.661 0.708 0.716 0.722 0.818 0.719 0.813 0.809 
no. comp 6 6 6 5 5 4 6 6 
s 0.069 0.024 0.026 0.119 0.342 0.390 0.322 0.371 
R2 0.999 1.000 1.000 0.996 0.933 0.910 0.943 0.921 
F 385.602 3203.643 2824.707 155.024 83.423 78.310 79.442 58.375 
Prob. R2=0 0.003 0.000 0.000 0.001 0.000 0.000 0.000 0.000 
Human MT 2 Table 6; Human MT 2 Table 6;; 
CoMFA CoMSJA CoMFAi CoMSIAi 
B E s B E s 
Q2 0.859 0.809 0.862 0.929 0.694 0.768 0.737 0.671 
no. comp 5 4 5 6 6 5 6 4 
s 0.187 0.338 0.182 0.164 0.151 0.125 0.092 0.235 
R2 0.987 0.953 0.988 0.991 0.996 0.996 0.999 0.981 
F 152.489 56.311 160.930 166.798 86.123 152.798 234.353 52.793 
Prob. R2=0 0.000 0.000 0.000 0.000 0.012 0.001 0.004 0.001 
• Alignment using MLT as the basic molecule b Outliers: 23a, 25a • Outliers: Sc, 25a, 30 d Outlier: Sc • Outlier: 21 d r Outlier: 21d g Outliers: 
20c, 21 d, 30 b Outliers: 21 d, 30 ; Outliers: 21 d ; Outliers: 2 I d 
Table 6a Set 6 CoMF A MT1 All 
EA PAB RESB PAE RESE PAS RESS 
CMPDOl 0.18 0.14 0.04 0.11 0.07 0.06 0.12 
CMPD02 -2.78 -2.81 0.03 -2.73 -0.05 -2.90 0.12 
CMPD05A -2.29 -2.10 -0.19 -1.97 -0.32 -2.17 -0.12 
CMPD05B -2.31 -2.55 0.24 -2.32 0.01 -2.61 0 .30 
CMPD05D -2.89 -3.03 0.14 -3.09 0.20 -3.03 0.14 
CMPD05E -3.08 -2.90 -0.18 -3.21 0.13 -2.96 -0.12 
CMPD07A -0.26 -0.64 0.38 -0.77 0.51 -0.69 0.43 
CMPD07B -0.64 -0.67 0.03 -0.80 0.16 -0.66 0.02 
CMPD07C -0.65 -0.35 -0.30 -0.31 -0.34 -0.40 -0.25 
CMPD07D -1.67 -1.73 0.06 -1.52 -0.15 -1.70 0.03 
73 
Table 6a Set 6 CoMFA MT1 All cont. 
EA PAB RESB PAE RESE PAS RESS 
CMPD10A -1.26 -1.30 0.04 -1.36 0.10 -1.30 0.04 
CMPD10B -1.16 -1.27 0.11 -1.38 0.22 -1.21 0.05 
CMPD10C -0.96 -0.95 -0.01 -1.02 0.06 -0.97 0.01 
CMPD10D -2.37 -2.27 -0.10 -2.11 -0.26 -2.22 -0.15 
CMPD13 -2.45 -2.16 -0.29 -2.13 -0.32 -2.05 -0.40 
CMPD20A -2.59 -2.26 -0.33 -2.45 -0.14 -2.21 -0.38 
CMPD20B -2.17 -2.17 0.00 -2.46 0.29 -2.07 -0.10 
CMPD20C -1.85 -2.21 0.36 -1.84 0.01 -2.13 0.28 
CMPD20D -3.31 -3.31 0.00 -3.28 -0.03 -3.30 -0.01 
CMPD21A -0.86 -0.91 0.05 -0.80 -0.06 -0.91 0.05 
CMPD21B -0.77 -0.80 0.03 -0.81 0.04 -0.74 -0.03 
CMPD21C -0.61 -0.54 -0.07 -0.53 -0.08 -0.52 -0.09 
CMPD23B -2.06 -1.59 -0.47 -1 .56 -0.50 -1 .61 -0.45 
CMPD23C -1.90 -2.14 0.24 -2.09 0.19 -1 .94 0.04 
CMPD23D -2.07 -2.35 0.28 -2.40 0.33 -2.44 0.37 
CMPD23E -2.40 -2.44 0.04 -2.55 0.15 -2.48 0.08 
CMPD25B -1.72 -1.87 0.15 -1 .90 0.18 -1.90 0.18 
CMPD25C -1.82 -1.74 -0.08 -1.76 -0.06 -1.80 -0.02 
CMPD25D -2.70 -2.60 -0.10 -2.51 -0.19 -2.63 -0.07 
CMPD25E -2.88 -2.93 0.05 -2.78 -0.10 -2.93 0.05 
CMPD27A -2.71 -2.64 -0.07 -2.62 -0.09 -2.68 -0.03 
CMPD27B -2.43 -2 .50 0.07 -2.57 0.14 -2 .48 0.05 
CMPD27C -2.41 -2.35 -0.06 -2.50 0.09 -2.36 -0.05 
CMPD27D -3.47 -3.40 -0.07 -3.31 -0.16 -3 .38 -0.09 
Modified PAB d PAE d PAS d 
CMPD33 ? -0.30 0.05 -0.45 -0.13 -0.40 O.ot 
CMPD34 ? -0.29 0.06 -0.78 -0.46 -0.38 0.02 
aMLT Luzindo1e 
Table 6b Set 6 CoMSIA MT1 All 
EA PA RES 
CMPD01 0.18 0.24 -0.06 
CMPD02 -2.78 -2.81 0.02 
CMPD05A -2.29 -2.13 -0.16 
CMPD05B -2.31 -2.29 -0.02 
CMPD05D -2.89 -2.66 -0.23 
CMPD05E -3 .08 -2.93 -0.15 
CMPD07A -0.26 -0.72 0.45 
CMPD07B -0.64 -0.59 -0.05 
CMPD07C -0.65 -0.24 -0.41 
CMPD07D -1.67 -1.61 -0.06 
CMPD10A -1.26 -1.46 0.20 
CMPD10B -1.16 -1.40 0.24 
CMPD10C -0.96 -1.04 0.08 
CMPD10D -2.37 -2.35 -0.02 
CMPD13 -2.45 -2.64 0.19 
CMPD20A -2.59 -2.19 -0.40 
CMPD20B -2.1 7 -2.29 0.12 
CMPD20C -1.85 -2.17 0.32 
CMPD20D -3.3 1 -3.20 -0.11 
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Table 6b Set 6 CoMSIA MT1 All 
EA PA RES 
CMPD21A -0.86 -1.04 0.18 
CMPD21B -0.77 -1.02 0.25 
CMPD21C -0.61 -0.74 0.13 
CMPD21D -2.64 -2.21 -0.43 
CMPD23A -2.38 -1.85 -0.53 
CMPD23B -2.06 -1.76 -0.30 
CMPD23C -1.90 -2.19 0.28 
CMPD23D -2.07 -2.60 0.53 
CMPD23E -2.40 -2.84 0.44 
CMPD25B -1.72 -1.77 0.05 
CMPD25C -1.82 -1.47 -0.35 
CMPD25D -2.70 -2.65 -0.05 
CMPD25E -2.88 -2.83 -0.05 
CMPD27A -2.71 -2.64 -0.07 
CMPD27B -2.43 -2.55 0.12 
CMPD27C -2.41 -2.26 -0.15 
CMPD27D -3.47 -3.44 -0.03 
Modified PA D. 
CMPD34 ? -0.17 0.07 
CMPD35 ? -1.36 -1.12 
CMPD36 ? -0.71 -0.47 
CMPD37 ? -0.50 -0.26 
CMPD38 ? -0.07 0.17 
CMPD39 ? -0.22 0.02 
Table 6c Set 6 CoMFA MTI 6i 
EA PAB RESB PAE RESE PAS RESS 
CMPD01 0.18 0.20 -0.02 0.17 0.01 0.09 0.10 
CMPD02 -2.78 -2.79 0.01 -2.80 0.02 -2.70 -0.08 
CMPD05A -2.29 -2.15 -0.14 -2.13 -0.16 -2.29 0.00 
CMPD05B -2.31 -2.28 -0.03 -2.34 0.03 -2.37 0.06 
CMPD05C -2.24 -2.15 -0.09 -2.06 -0.18 -2.17 -0.07 
CMPD05D -2.89 -3.14 0.25 -3.20 0.31 -3.20 0.31 
CMPD05E -3.08 -3.06 -0.02 -3.28 0.20 -3.16 0.08 
CMPD07 A -0.26 -0.53 0.27 -0.78 0.52 -0.59 0.33 
CMPD07B -0.64 -0.54 -0.10 -0.68 0.03 -0.50 -0.14 
CMPD07C -0.65 -0.59 -0.06 -0.55 -0.10 -0.46 -0.19 
CMPD07D -1.67 -1.63 -0.04 -1.52 -0.15 -1.62 -0.05 
CMPD10A -1.26 -1.18 -0.09 -1.37 0.11 -1.28 0.02 
CMPD10B -1.16 -1.21 0.05 -1.28 0.12 -1.22 0.06 
CMPD10C -0.95 -1.11 0.16 -1.09 0.14 -1.10 0.15 
CMPD10D -2.37 -2.20 -0.17 -2.19 -0.18 -2.15 -0.22 
CMPD13 -2.45 -2.48 0.03 -1.73 -0.72 -2.09 -0.37 
Modified PAB D. PAE D. PAS D. 
CMPD31 ? -1.43 -0.84 -0.51 0.04 -1.36 -0.90 
CMPD38 ? -0.47 0.12 -0.61 -0.06 -0.43 0.04 
CMPD39 ? -0.50 0.08 -0.46 0.09 -0.51 -0.05 
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Table 6d Set 6 CoMSIA MT1 6; Table 6f Set 6 CoMSIA MT 1 6;; 
EA PA RES EA PA RES 
CMPD01 0.18 0.19 -0.01 CMPD01 0.18 0.19 0.00 
CMPD02 -2.78 -2.78 0.00 CMPD02 -2.78 -2.78 0.00 
CMPD05A -2.29 -2.03 -0.26 CMPD20A -2.59 -2.49 -0.10 
CMPD05B -2.31 -2.37 0.06 CMPD20B -2.17 -2.23 0.06 
CMPD05D -2.89 -2.96 0.07 CMPD20C -1.85 -1.86 0.01 
CMPD05E -3.08 -3.09 0.01 CMPD20D -3.31 -3.32 0.01 
CMPD07 A -0.26 -0.52 0.26 CMPD21 A -0.86 -0.99 0.13 
CMPD07B -0.64 -0.64 0.00 CMPD21B -0.77 -0.78 0.01 
CMPD07C -0.65 -0.47 -0.18 CMPD21C -0.61 -0.50 -0.11 
CMPD07D -1.67 -1.65 -0.02 Modified PA !:J. 
CMPD10A -1.26 -1 .127 -0.13 CMPD41 ? -0.38 0.12 
CMPD10B -1.16 -1.28 0.12 CMPD42 ? -0.42 0.09 
CMPD10C -0.95 -1.04 0.09 CMPD43 ? -0.59 0.19 
CMPD10D -2.37 -2.24 -0.13 CMPD44 ? -0.62 0.16 
CMPD13 -2.45 -2.57 0.12 CMPD45 ? -0.56 0.22 
Modified PA !:J. CMPD46 ? -0.87 -0.08 
CMPD39 ? -0.30 0.18 CMPD47 ? -0.29 0.49 
CMPD48 ? -0.47 0.03 
Table 6e Set 6 CoMFA MT1 6;; 
EA PAB RESB PAE RESE PAS RESS 
CMPDOI 0.18 0.19 -0.01 0.18 0.00 0.18 0.00 
CMPD02 -2.78 -2.78 0.00 -2.78 0.00 -2.78 0.00 
CMPD20A -2.59 -2.55 -0.04 -2.59 0.00 -2.59 0.00 
CMPD20B -2.17 -2.16 -0.01 -2.18 O.oi -2.18 0.01 
CMPD20C -1.85 -1.90 0.05 -1.84 -0.01 -1.87 0.01 
CMPD20D -3.31 -3.32 0.01 -3.31 0.00 -3.30 -0.01 
CMPD21A -0.86 -0.92 0.06 -0.86 0.00 -0.87 0.01 
CMPD21 B -0.77 -0.74 -0.03 -0.75 -0.02 -0.74 -0.03 
CMPD21 C -0.61 -0.58 -0.03 -0.63 0.02 -0.61 0.00 
Modified PAB !:J. PAE !:J. PAS !:J. 
CMPD41 ? -0.47 0.11 -0.94 -0.31 -0.46 0.16 
CMPD42 ? -0.52 0.06 -0.90 -0.27 -0.50 O.ll 
CMPD43 ? -0.74 0.00 -0.80 -0.05 -0.59 0.15 
CMPD44 ? -0.77 -0.02 -0.80 -0.05 -0.59 0.15 
CMPD45 ? -0.78 -0.04 -1.42 -0.67 -0.61 0.13 
CMPD46 ? -0.61 0.13 -0.49 0.26 -0.61 0.13 
CMPD47 ? -0.74 0.00 -1.83 -1.08 -0.54 0.20 
CMPD48 ? -0.34 0.24 -0.73 -0.10 -0.33 0.28 
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Table 6g Set 6 CoMF A MT 2 All 
EA PAB RESB PAE RESE PAS RESS 
CMPDOl 0.48 0.45 0.03 0.72 -0.24 0.19 0.29 
CMPD02 -1.65 -1.61 -0.04 -2.04 0.39 -1.67 0.02 
CMPD05A -1.23 -1.46 0.23 -0.88 -0.35 -1.47 0.23 
CMPD05B -1.24 -1.62 0.38 -1.19 -0.05 -1.64 0.40 
CMPD05C -1.08 -0.79 -0.29 -0.93 -0.15 -0.90 -0.18 
CMPD05D -2.35 -2.17 -0.18 -2.16 -0.19 -2.22 -0.13 
CMPD05E -3.05 -2.34 -0.71 -2.69 -0.36 -2.71 -0.34 
CMPD07 A 1.22 0.83 0.39 0.89 0.33 0.85 0.37 
CMPD07B 0.77 1.11 -0.34 0.95 -0.18 1.13 -0.36 
CMPD07C 1.30 1.50 -0.20 1.42 -0.12 1.36 -0.06 
CMPD07D 0.02 0.04 -0.02 0.14 -0.12 0.02 0.00 
CMPD10A 0.68 0.11 0.57 0.08 0.60 0.17 0.51 
CMPD10B 0.59 0.41 0.18 0.17 0.42 0.53 0.06 
CMPD10C 0.80 0.80 0.00 0.49 0.31 0.77 0.03 
CMPD10D -0.74 -0.64 -0.10 -0.69 -0.05 -0.57 -0.17 
CMPD13 -1.53 -1.26 -0.27 -0.95 -0.58 -1.28 -0.25 
CMPD20A -1.56 -1.92 0.36 -1.79 0.23 -1.64 0.08 
CMPD20B -0.97 -1.45 0.48 -1.77 0.80 -1.20 0.23 
CMPD20D -2.55 -2.57 0.02 -2.50 -0.05 -2.44 -0.11 
CMPD21A 0.29 0.28 O.oi 0.58 -0.29 0.49 -0.20 
CMPD21B 0.92 0.81 0.11 0.61 0.31 1.01 -0.09 
CMPD21C 0.70 1.11 -0.41 0.90 -0.20 1.15 -0.45 
CMPD23A -2.35 -1.86 -0.49 -1.60 -0.75 -1.87 -0.48 
CMPD23B -1.66 -1.38 -0.28 -1.42 -0.24 -1.35 -0.31 
CMPD23C -1.80 -1.94 0.14 -1.71 -0.09 -1.78 -0.02 
CMPD23D -1.72 -2.24 0.52 -2.26 0.54 -2.21 0.49 
CMPD23E -2.49 -2.61 0.12 -2.87 0.38 -2.67 0.18 
CMPD25A -0.80 -0.50 -0.31 -0.40 -0.40 -0.63 -0.17 
CMPD25B -0.15 -0.28 0.13 -0.39 0.24 -0.33 0.18 
CMPD25C 0.30 -0.16 0.46 -0.16 0.46 -0.31 0.61 
CMPD25D -1.08 -1 .126 0.05 -0.99 -0.09 -1 .123 0.04 
CMPD25E -1.50 -1.62 0.12 -1 .232 -0.27 -1.76 0.26 
CMPD27 A -2.07 -1.51 -0.56 -1.42 -0.66 -1.50 -0.57 
CMPD27B -1.34 -1 .020 -0.32 -1.29 -0.05 -1 .00 -0.34 
CMPD27C -0.81 -0.96 0.15 -1 .139 0.33 -1 .04 0.23 
CMPD27D -1.93 -2.01 0.08 -2.06 0.13 -1 .95 0.02 
Modified PAB A PAE A PAS A 
CMPD33 ? 1.60 0.10 1.03 -0.39 1.43 0.07 
CMPD34 ? 1.58 0.08 0.87 -0.55 1.44 0.08 
CMPD38 ? 1.49 -0.01 0.72 -0.70 1.42 0.05 
77 
Table 6h Set 6 CoMSIA MT 2 All 
EA PA RES 
CMPD01 0.48 0.42 0.06 
CMPD02 -1.65 -1.61 -0.04 
CMPD05A -1.23 -1.17 -0.06 
CMPD05B -1.24 
-1.23 -0.01 
CMPD05C -1.08 -0.74 -0.34 
CMPD05D -2.35 -1.93 -0.43 
CMPD05E -3.05 -2.27 -0.79 
CMPD07 A 1.22 0.83 0.39 
CMPD07B 0.77 1.05 -0.28 
CMPD07C 1.30 1.48 -0.18 
CMPD07D 0.02 0.19 -0.17 
CMPD10A 0.68 -0.04 0.72 
CMPDIOB 0.59 0.16 0.43 
CMPD10C 0.80 0.55 0.25 
CMPD10D -0.74 -0.73 -0.01 
CMPD13 -1.53 -1.92 0.39 
CMPD20A -1.56 -1.53 -0.03 
CMPD20B -0.97 -1.36 0.39 
CMPD20C -0.57 -1.13 0.55 
CMPD20D -2.55 -2.60 0.05 
CMPD21A 0.29 0.59 -0.30 
CMPD21B 0.92 0.80 0.12 
CMPD21C 0.70 1.23 -0.53 
CMPD23A -2.35 -1.94 -0.42 
CMPD23B -1.66 -1.67 0.01 
CMPD23C -1.80 -1.86 0.06 
CMPD23D -1.72 -2.37 0.65 
CMPD23E -2.49 -2.71 0.22 
CMPD25A -0.80 -0.53 -0.27 
CMPD25B -0.15 -0.30 0.15 
CMPD25C 0.30 0.11 0.19 
CMPD25D -1.08 -1.00 -0.08 
CMPD25E -1.50 -1.43 -0.07 
CMPD27A -2.07 -1.48 -0.59 
CMPD27B -1.34 -1 .23 -0.11 
CMPD27C -0.81 -0.87 0.06 
CMPD27D -1.93 -1.93 0.00 
Modified PA fl 
CMPD38 ? 1.52 0.04 
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Table 6i Set 6 CoMFA MT2 6; 
EA PAB RESB PAE RES E PAS RESS 
CMPD01 0.48 0.50 -0.02 0.52 -0.04 0.35 0.13 
CMPD02 -1.65 -1.63 -0.02 -1.68 0.03 -1 .54 -0.11 
CMPD05A -1.23 -1.25 0.02 -1.16 -0.07 -1.13 -0.10 
CMPD05B -1.24 -1.38 0.14 -1.24 0.00 -1 .34 0.10 
CMPD05C -1.08 -1 .172 0.09 -1.13 0.05 -1.23 0.15 
CMPD05D -2.35 -2.47 0.12 -2.65 0.30 -2.44 0.09 
CMPD05E -3.05 -2.85 -0.20 -3.00 -0.05 -3.05 0.00 
CMPD07 A 1.22 1.04 0.18 0.79 0.43 1.10 0.12 
CMPD07B 0.77 1.14 -0.37 1.12 -0.35 1.12 -0.35 
CMPD07C 1.30 1.36 -0.06 1.33 -0.03 1.23 0.07 
CMPD07D 0.02 -0.09 0.11 0.02 0.00 -0.14 0.16 
CMPD10A 0.68 0.45 0.23 0.19 0.49 0.57 0.11 
CMPDIOB 0.59 0.57 0.02 0.56 0.03 0.61 -0.02 
CMPDIOC 0.80 0.80 0.00 0.74 0.06 0.76 0.04 
CMPDIOD -0.74 -0.63 -0.11 -0.68 -0.06 -0.50 -0.24 
CMPD13 -1.53 -1.41 -0.12 -0.76 -0.77 -1.40 -0.14 
Modified PAB ll PAE ll PAS ll 
CMPD33 ? 1.43 0.07 1.02 -0.32 1.11 -0.12 
CMPD34 ? 1.50 0.13 0.93 -0.40 1.14 -0.09 
CMPD39 ? 1.15 -0.21 1.44 0.10 1.06 -0.17 
Table 6j Set 6 CoMSIA MT 2 6; 
















CMPD13 -1 .53 
Modified PA ll 
CMPD38 ? 1.41 0.15 
CMPD39 ? 1.47 0.21 




Table 7; Set 7 - Group 1 Compounds 




cmpd02f H Me -3.73 
cmpd02g H Et -2.64 
cmpd02h H Pr -3.03 
cmpd02i H CH2Br -2.87 
cmpd02j H CF3 -3.67 
cmpd021 OMe Me -2.34 
cmpd02m OMe Et -1.61 
cmpd02n OMe Pr -2.75 
cmpd02o OMe CH2Br -0.92 
cmpd02p OMe CF3 -2.01 
cmpd02q OMe c-C3H5 -2.16 
Test Ori~nal Modification(s) 
cmpd12a cmpdOI OCH2CH3 
cmpd12b cmpdOI OCH(CH3h 
cmpd12c cmpdOl ~8H2CH3 
C!!!Edi2d cmpdOJ replace 0 with C=O 





Table 70 Set 7- Group 2 Compounds 




cmpd09a H Me -2.36 
cmpd09b H Et -2.31 
cmpd09c H Pr -2.33 
cmpd09e H c-C3H5 -3.65 
cmpd09g OMe Me 0.01 
cmpd09h OMe Et -0.16 
cmpd09i OMe Pr 0.42 
cmpd09j OMe C4H9 -1.91 
cmpd09k OMe c-C3H5 -1.48 
cmpd091 OMe c-C4H7 -2.43 
cmpd09m OMe CF3 -0.30 
cmpd09n OCF3 Me -2.15 
cmpd09o OCF3 Et -1.60 
cmpd09p OCF3 c-C4H7 -3.09 
cmpd09q Me Me -1.21 
cmpd09r Me Et -0.88 
cmpd09s Me c-C4H7 -2.74 
cmpd09t CJ Me -0.33 
cmpd09u Cl c-C3H5 -2.12 
cmpd09v Cl c-C4H7 -2.27 
cmpd09w Et Et -1.44 
Test Original Modification(s) 
cmpd13a cmpd09g NH2CH3 
cmpd13b cmpd09g C40H2CH3 
cmpd13c cmpd09g OCH2CH3 
cmpdl3d cmpd09g OCH(CH3h 
cmpd13e cmpd09g OCH20H 
cmpd14a cmpd09i NH2CH3 
cmpdl4b cmpd09i C 1H2CH3 
cmpdl4c cmpd09i OCH2CH3 
cmpdl4d cmpd09i OCH(CH3)z 
cmpdl4e cmpd09i OCH20H 
cmpdl4f cmpd09i C 1HFCH3 





Table 7m Set 7 - Group 3 Compounds Table 7;v Set 7 - Group 4 Compounds 








cmpd10a H Me -2.71 
cmpd11a H Me 
cmpd10b H Et -2.43 
cmpdllb H Et 
cmpdlOc H Pr -2.38 
cmpdllc H Pr 
cmpd10e H c-C3H5 -3.71 cmpd11d H c4~ 
cmpd10f H c-C4H7 -3.76 cmpd11e H c-C3H5 
cmpd10h OMe Me -2.21 
cmpd11f H c-C4H7 cmpd10i OMe Et -1.20 
cmpd11h OMe Me 
cmpd10j OMe Pr -1.36 
cmpdlli OMe Et 
cmpdlOk OMe c-C3H5 -2.66 cmpd11j OMe Pr 
• MLT b Luzindole c N-CBCPT 
cmpd11k OMe C4H9 
cmpd111 OMe c-C3H5 
cmpd11m OMe c-C4H7 
• MLT b Luzindole c N-CBCPT 
Table 7A 
Set 7: Summary of the Statistical Results for the PLS Analyses 14'a 
Ovine Pars Tuberalis Membrane Binding 
CoMFAb CoMSIAc 
B E s 
Q2 0.540 0.678 0.467 0.637 
no. comp 6 5 6 6 
s 0.286 0.356 0.341 0.371 
R2 0.942 0.908 0.918 0.888 
F 116.765 87.223 79.720 57.008 
Prob. R2- 0 0.000 0.000 0.000 0.000 
• Alignment using cmpdlOj as the basic molecule b Outliers: 2n, 9j, 9k, 91, 9n, lie< 





































































EA PAB RESB 
0.23 0.23 0.01 










-2.87 -2.92 0.05 
-3.67 -3.54 -0.13 
-2.34 -2.07 -0.27 
-1.61 -1.88 0.27 
-0.92 -1.08 0.16 
-2.01 -2.07 0.06 
-2.16 -1.83 -0.33 
-2.75 -3.13 0.38 
-2.36 -2.07 -0.29 
-2.31 -2.05 -D.26 
-2.33 -2.11 -0.22 
-3.65 -3.10 -D.55 
0.01 0.13 -0.12 
-0.16 -0.41 0.25 
0.42 0.13 0.30 
-0.30 -0.45 0.15 
-1.60 -1.47 -0.13 
-3.09 -3.17 0.08 
-1.21 -0.67 -0.54 
-0.88 -1.32 0.44 
-2.74 -2.50 -0.24 
-0.33 -0.67 0.34 
-2.12 -2.01 -0.11 
-2.27 -2.51 0.24 
-1.44 -1.86 0.42 
-2.71 -3.24 0.53 
-2.43 -2.34 -D.09 
-2.38 -2.36 -D.02 
-3.71 -3.74 0.03 
-3.76 -3.98 0.22 
PAE RESE PAS RESS 
0.16 0.07 0.17 0.06 
-3.33 0.12 -3.54 0.33 
-3.55 -0.19 -3.35 -D.38 
-2.86 0.22 -2.49 -D.15 
-2.86 -0.18 -2.64 -D.40 
-2.71 -0.16 -3.03 0.16 
-3.56 -0.12 -3.47 -D.21 
-1.97 -0.37 -1.94 -D.40 
-2.07 0.46 -1.73 0.12 
-1.28 0.36 -1.31 0.39 
-2.28 0.27 -1.86 -0.16 
-1.70 -0.46 -1.51 -0.66 
-2.61 -0.14 -3.03 0.28 
-2.42 0.06 -2.18 -D.18 
-2.32 0.01 -2.41 0.10 
-2.38 0.05 -2.44 0.11 
-3.03 -0.62 -3.12 -D.53 
0.56 -0.55 -0.08 0.09 
-0.19 0.03 -0.69 0.53 
0.24 0.18 -0.01 0.43 
-0.54 0.24 -0.24 -D.06 
-1.44 -0.16 -0.91 -0.69 
-3.21 0.12 -3.25 0.16 
-1.31 0.10 -0.55 -0.67 
-0.91 0.03 -1.49 0.61 
-3.02 0.28 -2.25 -0.49 
-0.86 0.53 -0.38 0.05 
-2.13 0.01 -2.10 -0.02 
-3.00 0.73 -2.47 0.20 
-1.60 0.16 -1.65 0.21 
-3.14 0.43 -3.28 0.57 
-2.52 0.09 -2.54 0.11 
-2.47 0.09 -2.44 0.06 
-3.55 -0.16 -3.70 -0.01 
-3.58 -0.18 -3.86 0.10 
-2.21 -1.97 -D.24 -1.65 -0.56 
-2.03 -0.18 
-1.20 -1.00 -D.20 -1.15 -0.05 
-1.14 -0.06 
-1.36 -1.08 -D.28 -0.98 -0.38 
-1.17 -0.19 
-2.66 -2.63 -D.03 -2.36 -0.30 
-2.37 -0.29 
-2.63 -2.35 -D.29 -2.80 0.17 
-2.52 -0.11 
-2.11 -2.36 0.25 -2.66 0.55 
-2.44 0.33 
-3.92 -3.80 -0.12 -3.27 -0.65 
-3.92 0.00 
-3.09 -2.98 -D.12 -3.26 0.17 
-2.98 -0.11 
-3.23 -3.17 -D.06 -3.17 -0.06 
-3.40 0.17 
-1.38 -1.15 -0.23 -1.43 0.05 
-1.44 0.06 
-0.85 -0.95 0.10 -1.31 0.46 
-1.03 0.18 
-1.01 -1.64 0.63 -1.22 0.21 
-1.70 0.69 
-2.67 -2.59 -0.08 -1.70 -0.98 
-2.71 0.04 
-1.65 -1.65 0.00 -1.85 0.20 
-1.60 -0.05 
-2.16 -1.83 -0.33 -1.99 -0.17 
-2.04 -0.12 
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Table 7a Set 7 CoMFA cont. 
Modified PAB A PAE A PAS A 
CMPD12A ? 0.17 -0.06 0.27 0.11 0.19 0.01 
CMPD12B ? 0.10 -0.12 -1.08 -1.24 -0.10 -0.28 
CMPD12C ? 0.28 0.06 0.30 0.15 0.41 0.24 
CMPD12D ? -0.48 -0.71 -1.04 -1.20 -0.67 -0.84 
CMPD13A ? 0.15 0.02 0.72 0.16 -0.06 0.02 
CMPD13B ? -0.35 -0.48 0.54 -0.02 -0.06 0.02 
CMPD13C ? 0.00 -0.13 0.67 0.11 -0.20 -0.12 
CMPD13D ? -0.10 -0.23 0.31 -0.25 -0.45 -0.37 
CMPD13E ? 0.05 -0.08 0.15 -0.41 -0.19 -0.11 
CMPD14A ? 0.17 0.04 0.39 0.14 0.07 0.15 
CMPD14B ? -0.18 -0.30 0.38 0.13 -0.46 -0.38 
CMPD14C ? -0.01 -0.13 0.74 0.50 -0.17 -0.09 
CMPD14D ? -0.02 -0.14 0.79 0.55 -0.43 -0.35 
CMPD14E ? 0.19 0.07 0.99 0.75 -0.16 -0.08 
CMPD14F ? 0.49 0.37 0.64 0.39 -0.01 0.07 
Table 7b Set 7 CoMSIA 
EA PA RES 
CMPD01 0.23 0.18 0.06 
CMPD02 -3.21 -3.03 -0.18 
CMPD02F -3.73 -3.20 -0.54 
CMPD02G -2.64 -3.10 0.46 
CMPD02H -3.03 -3.25 0.22 
CMPD021 -2.87 -2.90 0.03 
CMPD02J -3.67 -3.41 -0.26 
CMPD02L -2.34 -1.94 -0.41 
CMPD02M -1.61 -2.08 0.47 
CMPD02N -2.75 -2.46 -0.29 
CMPD020 -0.92 -1.49 0.57 
CMPD02P -2.01 -2.10 0.09 
CMPD02Q -2.16 -1.88 -0.28 
CMPD03 -2.75 -2.50 -0.25 
CMPD09A -2.36 -2.38 0.02 
CMPD09B -2.31 -2.13 -0.18 
CMPD09C -2.33 -2.77 0.44 
CMPD09E -3.65 -3.13 -0.52 
CMPD09G 0.01 -0.08 0.09 
CMPD09H -0.16 -0.80 0.64 
CMPD09J -1.91 -1.75 -0.16 
CMPD09K -1.48 -1.42 -0.06 
CMPD09L -2.43 -2.17 -0.26 
CMPD09M -0.30 0.08 -0.38 
CMPD090 -1.60 -1.22 -0.38 
CMPD09P -3.09 -3.63 0.54 
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Table 7b Set 7 CoMSIA cont. 
EA PA RES 
CMPD09R -0.88 -0.69 -0.19 
CMPD09S -2.74 -3.06 0.32 
CMPD09T -0.33 -0.44 0.11 
CMPD09U -2.12 -1.83 -0.29 
CMPD09W -1.44 -1.62 0.18 
CMPDIOA -2.71 -2.72 O.ot 
CMPD10B -2.43 -2.68 0.25 
CMPD10C -2.38 -2.68 0.30 
CMPD10E -3.71 -3.12 -0.59 
CMPD10F -3.76 -4.14 0.38 
CMPDIOH -2.21 -1.62 -0.59 
CMPD101 -1.20 -1.62 0.42 
CMPD10J -1.36 -1.63 0.27 
CMPD10K -2.66 -2.31 -0.35 
CMPD11A -2.63 -2.21 -0.42 
CMPD11B -2.11 -2.60 0.49 
CMPD11D -3.92 -3.63 -0.29 
CMPD11E -3.09 -3.00 -0.09 
CMPD11F -3.23 -3.15 -0.08 
CMPD11H -1.38 -1.14 -0.24 
CMPD111 -0.85 -1.53 0.68 
CMPD11K -2.67 -2.58 -0.09 
CMPDllL -1.65 -1.91 0.26 
CMPD11M -2.16 -2.25 0.09 
Modified EA PA 6. 
CMPD12A ? 0.37 0.20 
CMPD12B ? 0.53 0.35 
CMPD12C ? 0.03 -0.14 
CMPD12D ? -0.75 -0.93 
CMPD13A ? -0.08 0.00 
CMPD13B ? -0.36 -0.28 
CMPD13C ? 0.12 0.20 
CMPD13D ? 0.34 0.42 
CMPD13E ? 0.51 0.59 
CMPD14A ? -1.46 -0.01 
CMPD14B ? -1.66 -0.21 
CMPD14C ? -1.21 0.24 
CMPD14D ? -1.01 0.44 
CMPD14E ? -0.63 0.82 
CMPD14F ? -1.19 0.27 
CMPD091 ? -1.45 0.00 
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7-9 and 13-47 
Table 8 Set 8 ComQounds 
Compound R, R MT1 MT2 Table 8 Set 8 Co!!!Eounds cont 
cmpd01 0.40 0.52 Compound R• R MT1 MT2 
cmpd07 H Me -1.48 -0.63 cmpd37 Ph Me -1.60 -1.95 
cmpd08 H Et -0.82 -0.26 cmpd38 Ph Et -1.12 -1.00 
cmpd09 H n-Pr -1.00 -0.57 cmpd39 Ph n-Pr -1.78 -1.23 
cmpd13 Me Me -1.38 -0.72 cmpd40 Ph i-Pr -1.94 -1.76 
cmpd14 Me Et -0.45 -0.45 cmpd41 Ph c-Pr -1.36 -1.58 
cmpd15 Me n-Pr -0.36 -0.34 cmpd42 Ph NHEt -2.53 -1.79 
cmpd16 Me i-Pr -0.48 -0.36 cmpd43 Ph(CH2) 4 Me -0.11 -1.20 
cmpd17 Me c-Pr 0.15 -0.43 cmpd44 Ph(CH2) 4 Et 0.12 -1.15 
cmpd18 Me NHEt -1.70 -1.41 cmpd45 Ph(CH2) 4 n-Pr -0.52 -1.46 
cmpd19 Et Me -0.95 -0.36 cmpd46 Ph(CH2) 4 i-Pr -0.11 -1.26 
cmpd20 Et Et -0.54 0.00 cmpd47 Ph(CH2) 4 c-Pr 0.20 -1.34 
cmpd21 Et n-Pr -0.91 0.00 Test Original Modification{ s} 
cmpd22 Et i-Pr -1.12 -0.65 cmpd48 cmpd47 ~5Br 
cmpd23 Et c-Pr -0.65 -0.67 cmpd49 cmpd47 ~~r 
cmpd24 Et NHEt -1.88 -1.08 cmpd50 cmpd47 ~~r 
cmpd25 n-Pr Me -2.26 -1.54 cmpd51 cmpd47 ~8(CH3h 
cmpd26 n-Pr Et -1.71 -1.43 cmpd52 cmpd47 C 15CHr 
cmpd27 n-Pr n-Pr -2.22 -1.34 
cmpd28 n-Pr i-Pr -1.78 -1.46 cmpd53 cmpd44 ~
5Br 
cmpd29 n-Pr c-Pr -1.64 -0.88 cmpd54 cmpd44 ~~r 
cmpd30 n-Pr NHEt -2.69 -1.56 cmpd55 cmpd44 C
150H-
cmpd31 i-Pr Me -2.06 -1.54 cmpd56 cmpd44 ~8Br 
cmpd32 i-Pr Et -2.15 -1.18 cmpd57 cmpd44 c'sCHr 
cmpd33 i-Pr n-Pr -2.08 -1.20 cmpd58 cmpd44 ~8CHr 
cmpd34 i-Pr i-Pr -1.60 -1.94 cmpd59 cmpdl4 R:tBu 
cmpd35 i-Pr c-Pr -1.53 -2.06 cmpd60 cmpd14 R1: -CBr2CH3 




Set 8: Summary of the Statistical Results for the PLS Analyses 2,a 
HumanMT 1 HumanMT2 
CoMFAb CoMSIAc CoMFAd CoMSIAe 
B E s B E s 
Q2 0.765 0.736 0.670 0.786 0.555 0.581 0.561 0.533 
no. comp 6 5 5 5 2 3 2 6 
s 0.170 0.231 0.211 0.258 0.277 0.224 0.268 0.243 
R2 0.969 0.941 0.950 0.924 0.790 0.868 0.804 0.862 
F' 139.308 88.605 106.922 73.128 56.598 63.505 61.543 31.116 
Prob. R2=0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
'Alignment using cmpd27 as the basic molecule b Outliers: 7, 13, 20, 32, 38 <Outliers: 7, 13, 38 4 Outliers: 18, 19, 20, 21, 38, 40 <Outlier: 40 
Table 8a Set 8 CoMFA MT1 
EA PAB RESB PAE RESE PAS RESS 
CMPDOl 0.40 0.38 0.02 0.34 0.06 0.45 -0.05 
CMPD08 -0.82 -0.80 -0.02 -0.70 -0.13 -0.72 -0.10 
CMPD09 -1.00 -1.05 0.05 -0.69 -0.31 -0.94 -0.06 
CMPD14 -0.45 -0.45 0.00 -0.72 0.27 -0.52 0.07 
CMPD15 -0.36 -0.71 0.35 -0.76 0.40 -0.75 0.39 
CMPD16 -0.48 -0.35 -0.13 -0.48 0.00 -0.36 -0.12 
CMPD17 0.15 0.12 0.03 -0.13 0.28 0.01 0.14 
CMPD18 -1.70 -1.35 -0.35 -1.29 -0.41 -1.23 -0.47 
CMPD19 -0.95 -1.04 0.09 -0.91 -0.04 -1.13 0.18 
CMPD21 -0.91 -1.01 0.10 -1.11 0.20 -1.25 0.34 
CMPD22 -1.12 -0.97 -0.15 -0.83 -0.30 -1.00 -0.12 
CMPD23 -0.65 -0.74 0.09 -0.82 0.17 -0.74 0.09 
CMPD24 -1.88 -1.96 0.08 -1.75 -0.13 -1.88 0.00 
CMPD25 -2.26 -2.16 -0.10 -2.31 0.05 -2.27 0.01 
CMPD26 -1.71 -1.79 0.08 -1.94 0.23 -1.88 0.17 
CMPD27 -2.22 -2.07 -0.15 -1.98 -0.24 -2.07 -0.15 
CMPD28 -1.78 -1.93 0.15 -1.70 -0.08 -2.03 0.25 
CMPD29 -1.64 -1.60 -0.04 -1.76 0.12 -1.63 -0.01 
CMPD30 -2.69 -2.73 0.04 -2.70 O.ot -2.62 -0.07 
CMPD31 -2.06 -1.68 -0.38 -1.75 -0.31 -1.72 -0.34 
CMPD33 -2.08 -1.96 -0.12 -2.02 -0.06 -1.89 -0.19 
CMPD34 -1.60 -1.67 0.07 -1.70 0.10 -1.64 0.04 
CMPD35 -1.53 -1.53 -1.68 0.15 -1.43 -0.10 
CMPD36 -2.29 -2.64 0.35 -2.63 0.34 -2.49 0.20 
CMPD37 -1.60 -1.60 0.00 -1.53 -0.07 -1.73 0.13 
CMPD39 -1.78 -1.87 0.09 -1.82 0.04 -1.84 0.06 
CMPD40 -1.94 -1.90 -0.04 -1.76 -0.18 -1.82 -0.12 
CMPD41 -1.36 -1.36 0.00 -1.45 0.09 -1.39 0.03 
CMPD42 -2.53 -2.50 -0.03 -2.45 -0.08 -2.43 -0.10 
CMPD43 -0.11 -0.19 0.08 -0.17 0.06 -0.39 0.28 
CMPD44 0.12 -0.05 0.17 -0.2 1 0.33 -0.02 0.14 
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Table 8a Set 8 CoMFA MT1 
EA PAB RESB PAE RESE PAS RESS 
CMPD45 -0.52 -0.28 -0.24 -0.22 -0.30 -0.12 -0.40 
CMPD46 -0.11 -0.17 0.06 0.18 -0.29 -0.13 0.02 
CMPD47 0.20 0.26 -0.06 0.16 0.04 0.33 -0.13 
Modified PAB !J. PAE !J. PAS !J. 
CMPD48 ? 0.20 -0.05 0.10 -0.07 0.35 0.02 
CMPD49 ? 0.22 -0.04 0.28 0.12 0.33 0.00 
CMPD50 ? 0.32 0.06 0.20 0.03 0.32 -0.01 
CMPD51 ? 0.25 -0.01 0.14 -0.02 0.22 -0.12 
CMPD52 ? 0.22 -0.04 0.38 0.21 0.23 -0.10 
CMPD53 ? -0.06 0.00 -0.39 -0.19 0.06 0.09 
CMPD54 ? -0.06 -0.01 -0.10 0.11 -0.02 0.00 
CMPD55 ? -0.14 -0.09 -0.70 -0.50 0.02 0.05 
CMPD56 ? 0.09 0.14 -0.15 0.05 -0.04 -0.01 
CMPD57 ? -0.06 0.00 0.32 0.52 -0.07 -0.04 
CMPD58 ? 0.25 0.30 0.00 0.21 0.14 0.16 
CMPD59 ? -1.31 -0.86 -1.95 -1.22 -1.33 -0.81 
CMPD60 ? -0.27 0.18 -0.55 0.17 -0.23 0.30 
CMPD61 ? -0.35 0.10 -0.66 0.06 -0.45 0.07 
Table 8b Set 8 CoMSlA MTI Table 8b Set 8 CoMSlA MTI 
EA PA RES EA PA RES 
CMPD01 0.40 0.73 -0.33 CMPD36 -2.29 -2.54 0.25 
CMPD08 -0.82 -0.50 -0.32 CMPD37 -1.60 -1.62 0.02 
CMPD09 -1.00 -0.72 -0.28 CMPD39 -1.78 -1.95 0.17 
CMPD14 -0.45 -0.52 0.07 CMPD40 -1.94 -1.61 -0.33 
CMPD15 -0.36 -0.81 0.45 CMPD41 -1.36 -1.38 0.02 
CMPD16 -0.48 -0.42 -0.07 CMPD42 -2.53 -2.50 -0.03 
CMPD17 0.15 0.05 0.10 CMPD43 -0.1 1 -0. 17 0.06 
CMPD18 -1.70 -1.27 -0.43 CMPD44 0.12 -0.25 0.37 
CMPD19 -0.95 -1.05 0.10 CMPD45 -0.52 -0.46 -0.06 
CMPD20 -0.54 -1.12 0.58 CMPD46 -0.11 -0.10 -0.01 
CMPD21 -0.91 -1.39 0.48 CMPD47 0.20 0.08 0.12 
CMPD22 -1.12 -0.99 -0.13 Modified PA !J. 
CMPD23 -0.65 -0.79 0.14 CMPD48 ? 0.32 0.24 
CMPD24 -1 .88 -1.87 -0.01 CMPD49 ? 0.06 -0.02 
CMPD25 -2.26 -2.14 -0.12 CMPD50 ? -0.01 -0.09 
CMPD26 -1.71 -1.82 0.11 CMPD51 ? 0.11 0.04 
CMPD27 -2.22 -2.07 -0.16 CMPD52 ? 0.28 0.20 
CMPD28 -1.78 -1.69 -0.09 CMPD53 ? 0.18 0.43 
CMPD29 -1.64 -1.55 -0.09 CMPD54 ? -0.28 -0.03 
CMPD30 -2.69 -2.82 0.13 CMPD55 ? -0.29 -0.04 
CMPD31 -2.06 -1.71 -0.35 CMPD56 ? -0.30 -0.05 
CMPD32 -2.15 -1.81 -0.34 CMPD57 ? 0.03 0.28 
CMPD33 -2.08 -2.04 -0.04 CMPD58 ? -0.12 0.13 
CMPD34 -1.60 -1.69 0.09 CMPD59 ? -1.76 -1.25 
CMPD35 -1.53 -1.45 -0.08 CMPD60 ? -0.36 0.16 
CMPD61 ? -0.92 -0.41 
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Table 8c Set 8 CoMF A MT 2 
EA PA B RES B PA E RES E PA S RES S 
CMPD01 0.52 0.55 -0.03 0.49 0.04 0.59 -0.07 
CMPD07 -0.63 -0.42 -0.21 -0.58 -0.05 -0.34 -0.29 
CMPD08 -0.26 -0.35 0.09 -0.38 0.12 -0.30 0.04 
CMPD09 -0.57 -0.38 -0.19 -0.29 -0.29 -0.37 -0.20 
CMPD13 -0.72 -0.63 -0.09 -0.69 -0.03 -0.57 -0.15 
CMPD14 -0.45 -0.57 0.12 -0.51 0.06 -0.53 0.08 
CMPD15 -0.34 -0.59 0.25 -0.42 0.08 -0.60 0.26 
CMPD16 -0.36 -0.59 0.23 -0.54 0.18 -0.58 0.22 
CMPD17 -0.43 -0.61 0.18 -0.40 -0.03 -0.59 0.16 
CMPD22 -0.65 -1.04 0.39 -0.74 0.09 -1.06 0.41 
CMPD23 -0.67 -1.08 0.41 -0.88 0.21 -1.09 0.42 





















































































































































































Table 8d Set 8 CoMSIA MT2 
EA PA RES 
CMPD01 0.52 0.52 0.00 
CMPD07 
-0.63 -0.59 -0.04 
CMPD08 -0.26 -0.44 0.18 
CMPD09 -0.57 -0.54 -0.03 
CMPD13 -0.72 -0.53 -0.19 
CMPD14 -0.45 -0.36 -0.09 
CMPD15 -0.34 -0.48 0.14 
CMPD16 
-0.36 -0.59 0.23 
CMPD17 -0.43 -0.55 0.12 
CMPD18 -1.41 -1.01 -0.40 
CMPD19 -0.36 -0.63 0.27 
CMPD20 0.00 -0.48 0.48 
CMPD21 0.00 0.34 -0.34 
CMPD22 -0.65 -0.70 0.05 
CMPD23 -0.67 -0.58 -0.09 
CMPD24 -1.08 -1.13 0.04 
CMPD25 -1.54 -1.48 -0.06 
CMPD26 -1.43 -1.08 -0.35 
CMPD27 -1.34 -1.19 -0.15 
CMPD28 -1.46 -1.33 -0.13 
CMPD29 -0.88 -1.21 0.33 
CMPD30 -1.56 -1.55 -0.01 
CMPD31 -1.54 -1.44 -0.10 
CMPD32 -1.18 -1.28 0.10 
CMPD33 -1.20 -1.38 0.18 
CMPD34 -1.94 -1.52 -0.42 
CMPD36 -1.72 -1.92 0.20 
CMPD37 -1.95 -1.48 -0.47 
CMPD38 -1.00 -1.32 0.32 
CMPD39 -1.23 -1.43 0.20 
CMPD41 -1.58 -1.44 -0.14 
CMPD42 -1.79 -1.93 0.14 
CMPD43 -1.20 -1.33 0.13 
CMPD44 -1.15 -1.16 0.01 
CMPD45 -1.46 -1.27 -0.19 
CMPD46 -1.26 -1.40 0.14 
CMPD47 -1.34 -1.27 -0.07 
Modified PA t'J. 
CMPD48 ? -1.25 0.02 
CMPD49 ? -1.40 -0.14 
CMPD50 ? -1.12 0.15 
CMPD51 ? -1.41 -0.14 
CMPD52 ? -1.31 -0.04 
CMPD53 ? -0.99 0.17 
CMPD54 ? -1.29 -0.13 
CMPD55 ? -1.38 -0.22 
CMPD56 ? -1.22 -0.06 
CMPD57 ? 
-1.38 -0.2 1 
CMPD58 ? -1.15 O.Ql 
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